Document:

<PAGE>

                                                                    EXHIBIT 10.7

Confidential Materials omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote omissions.

                       DEVELOPMENT AND SUPPLY AGREEMENT

     This Development and Supply Agreement (the "Agreement"), effective as of
March 19, 1999 (the "Effective Date"), is made by and between LUMINEX
CORPORATION, a Delaware corporation with principal offices at 12212 Technology
Boulevard, Austin, Texas 78727 ("LUMINEX"), and BIO-RAD LABORATORIES, INC., a
Delaware corporation with principal offices at 1000 Alfred Nobel Drive,
Hercules, California 94547 ("BIO-RAD").

                                   BACKGROUND

     A.   LUMINEX has developed Standard Beads (as defined below) for detection
and quantification of analytes, either singly or in multiplexed (multiple
analytes simultaneously) form and is developing a system for use with such
Standard Beads.

     B.   BIO-RAD is an international company which manufactures and sells a
wide variety of research and clinical diagnostics products used in healthcare,
scientific investigation and industry.

     C.   The parties desire that BIO-RAD develop and distribute Kits
incorporating Tests (as defined below) for use within certain fields, and that
BIO-RAD distribute Luminex100 Systems (as defined below) as incorporated into
BIO-RAD's instrumentation.

     NOW THEREFORE, for and in consideration of the covenants, conditions, and
undertakings hereinafter set forth, it is agreed by and between the parties as
follows:

                                   ARTICLE 1

                                  DEFINITIONS
                                  -----------

     1.1  "Affiliate" means any entity which controls, is controlled by or is
           ---------
under common control with a party hereto. For such purposes, "control" shall
mean ownership of more than fifty percent (50%) of the shares of the subject
entity entitled to vote in the election of directors (or, in the case of an
entity that is not a corporation, for the election of the corresponding managing
authority).

     1.2  "Beads" means Standard Beads and Magnetic Beads.
           -----
     1.3  "Bead Specifications" means the specifications for the Standard
           -------------------
Beads or Magnetic Beads as designated by LUMINEX from time to time in writing.

     1.4 "BIO-RAD Improvement Patents" means patents issued during the term of
          ---------------------------
this Agreement in inventions comprising modifications, extensions or
enhancements conceived or reduced to practice by BIO-RAD to the Standard Beads
or Luminex100 Systems or portions thereof (including Included Software) or to
the manufacture or use of the Standard Beads, Luminex100 Systems or portions
thereof (including Included Software). "BIO-RAD Improvement Patents"
specifically excludes patent claims conceived and reduced to practice by BIO-RAD
consisting of methods of sample preparation, methods of conjugating Standard
Beads to analytes, the composition of matter of the specific chemistries of the
assays developed by BIO-RAD, methods of performing the assays (i.e., the
protocol for the assay) and methods of introducing the patient sample into the
BIO-RAD System.

     1.5  "BIO-RAD System" means the Luminex100 System as incorporated into
           --------------
BIO-RAD's instrumentation.

     1.6  "End User" shall mean a purchaser of Kits that obtains Kits for the
           --------
purpose of generating Test results on behalf of itself or third parties and not
for the purpose of re-sale of the Kit.

                                       1
<PAGE>

     1.7  "Fields" means the fields set forth in Exhibit A and any such other
           ------
fields as the parties include hereunder pursuant to Section 3.3. Fields One, Two
and Three as set forth in Exhibit A shall be limited to use in the human
clinical diagnostics industry.

     1.8  "Included Software" means [**]
           -----------------

     1.9  "Intellectual Property Rights" means (i) patent claims to the extent
           ----------------------------
such claims cover only an apparatus or composition of matter, and not a method
or process; and (ii) copyrights.

     1.10 "Kit" means the combination of (i) Standard Beads or Magnetic Beads
           ---
conjugated to biological reactants, (ii) standards, and (iii)  other ancillary
materials supplied by BIO-RAD, e.g. buffers and other solutions, required for
performance of Tests.  In order to qualify as a "Kit," it must contain all of
the foregoing components and not one or a subset of the foregoing components and
must be made generally available to BIO-RAD's customers.  Except as otherwise
agreed by LUMINEX and BIO-RAD, "Kits" shall not be designed for use in a
Multiplexed Bead Assay of more than one hundred (100) analytes.

     1.11 "Luminex100 System" means a laser based fluorescent analytical test
           -----------------
system consisting of LUMINEX's instrumentation marketed under the name
Luminex100 and the Software with or without off-the-shelf computer components
(selection of off-the-shelf computer components to be by LUMINEX), and any
functional replacements and line extensions, of the Luminex100 System, including
autosampler-based versions, in each case to the extent made generally available
by LUMINEX to its customers.

     1.12 "Luminex100 System Specifications" means the specifications for the
           --------------------------------
Luminex100 System as designated by LUMINEX from time to time in writing.

     1.13 "Magnetic Beads" means magnetic microsphere beads supplied [**] and
           --------------
dyed and modified by LUMINEX for use with Luminex100 Systems.

     1.14 "Multiplexed Bead Assays" means a number of assays derived from the
           -----------------------
use of fluorescently-dyed microsphere beads with said assays determined
simultaneously on a single sample.

     1.15 "Net Sales" means the total amounts invoiced by BIO-RAD to End Users,
           ---------
Subdistributors or other third parties with respect to the sale or other any
other provision of Kits, less all (i) volume discounts, rebates, and returns;
(ii) customs duties, taxes (e.g., sales, excise, withholding, and value-added
taxes) other than taxes based upon BIO-RAD's income; and (iii) freight,
insurance and other shipment expenses.

     1.16 "Panel" means a specified series or group of Tests.
           -----

     1.17 "Registration Code" means a unique identifier code incorporated into
           -----------------
Standard Beads and Magnetic Beads, which code would enable the Software to
identify BIO-RAD as the customer for whom the Standard Beads or Magnetic Beads
were initially supplied, each analyte measured using the Standard Beads or
Magnetic Beads in a particular Test, and other information.

---------------
[**]  Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.

                                       2
<PAGE>

     1.18  "Software" means the software programs in machine executable object
            --------
code format incorporated by LUMINEX into the Luminex100 System, and Updates
thereto, in each case that are made available by LUMINEX generally to its
customers as part of the Luminex100 System.

     1.19  "Specifications" means the Bead Specifications and Luminex100 System
            --------------
Specifications.

     1.20  "Standard Beads" means LUMINEX's standard fluorescently-dyed
            --------------
microsphere beads supplied by LUMINEX for use with Luminex100 Systems and made
available generally by LUMINEX to its customers.

     1.21  "Test" means a single use of Standard Beads or Magnetic Beads in the
            ----
detection or quantification of an analyte within the Fields for an application
within the Fields.

     1.22  "Updates" means error corrections and bug fixes to the Software that
            -------
LUMINEX makes generally available to its customers free of charge.

                                   ARTICLE 2

                                  DEVELOPMENT
                                  -----------
     2.1  Development.
          -----------

          (a)  BIO-RAD shall be responsible, at its expense, for all Kit design
and development hereunder.

          (b)  BIO-RAD further shall be responsible, at its expense, for
performing all activities required to secure and maintain all required
regulatory approvals for use of Kits and the BIO-RAD System within the Fields.
LUMINEX will cooperate with BIO-RAD, at BIO-RAD's expense, to the extent
LUMINEX's participation is necessary for BIO-RAD to obtain regulatory approval
for the Kits and BIO-RAD System for use within the Fields. LUMINEX will make
available to BIO-RAD [**] such tangible written information in LUMINEX's
possession and control as is necessary to obtain regulatory approval for the
Kits, it being understood that LUMINEX shall not be required to perform any
tests or studies required for regulatory approval.

          (c)  LUMINEX may, at BIO-RAD's request and on the terms acceptable to
both parties, conduct initial feasibility studies and/or contract manufacturing
for BIO-RAD.

          (d)  Subject to the terms and conditions of this Section 2.1(d),
LUMINEX shall use reasonable efforts to treat the Magnetic Beads provided to
LUMINEX by if feasible in LUMINEX's judgment, to permit use of such Magnetic
Beads with the Luminex100 System ("Services"). Such Services shall be subject to
LUMINEX's standard nonrecurring engineering fees then in effect; provided that
BIO-RAD shall not be obligated to pay LUMINEX in excess of [**] Dollars ($[**])
in the aggregate for the Services, and LUMINEX shall not be obligated to provide
services which at LUMINEX's standard rates exceed [**] Dollars ($[**]) with
respect to such Services. It is understood and agreed that LUMINEX's treatment
and BIO-RAD's sale of Magnetic Beads for use with the Luminex100 System will be
subject to LUMINEX's production of a beadmap for the Magnetic Beads that is
acceptable to LUMINEX as determined in accordance with criteria to be set forth
in the Development Agreement (as defined below). BIO-RAD's rights hereunder with
respect to Magnetic Beads shall be subject to agreement upon a tolling fee
payable by BIO-RAD to LUMINEX with respect to each Magnetic Bead dyed for use
with the Luminex100 System or BIO-RAD System. Such supply of Magnetic Beads by
BIO-RAD, the tolling fees payable by BIO-RAD with respect to Magnetic Beads and
any Services provided by LUMINEX with respect to Magnetic Beads is subject to
agreement on the terms and conditions of a development, services and supply
agreement to be negotiated in good faith by the parties ("Development
Agreement"). Notwithstanding any provision of this Agreement to the contrary,
including the provisions of Section 8.3, if the parties do not agree upon a
tolling fee for Magnetic Beads

________________
[**]  Indicates that materials has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.

                                       3
<PAGE>

within one hundred eighty (180) days of the Effective Date, all rights of BIO-
RAD and all obligations of LUMINEX with respect to Magnetic Beads shall
automatically terminate unless otherwise agreed in writing.

     2.2  Commercialization.  BIO-RAD shall (i) evaluate and determine in good
          -----------------
faith whether regulatory approval is required in each country in which it elects
to market or distribute the Kits and/or BIO-RAD Systems for use within the
Fields and shall obtain all regulatory approvals BIO-RAD so determines are
required for such marketing and distribution; and (ii) have sold Kits for which
a royalty is owed pursuant to Section 4.6(c) (including a Kit within Field Four)
and have commenced marketing, distribution and commercial sale of BIO-RAD
Systems, in each of (i) and (ii) within [**] months after the availability of
the Luminex100 System. BIO-RAD shall have [**] days to file regulatory approvals
which BIO-RAD determined in its good faith judgment were not required but with
respect to which BIO-RAD was later notified by the applicable government agency
were required. Failure by BIO-RAD to comply with (i) and (ii) with respect to
Field Four shall give LUMINEX the right at its sole election to terminate [**]
of Article 3.2 (b) by written notice to BIO-RAD, except to the extent caused
solely by LUMINEX's failure to supply Standard Beads or Luminex100 Systems in
accordance with the terms hereof or the Development Agreement.

     2.3  Other.  Without limiting the foregoing provisions of this Article 2,
          -----
BIO-RAD hereby agrees to keep LUMINEX reasonably informed as to the progress of
the activities undertaken pursuant to this Article 2.

                                   ARTICLE 3
                                 DISTRIBUTION
                                 ------------

     3.1  Appointment; Covenant Not to Sue. Subject to the terms and conditions
          --------------------------------
of this Agreement, LUMINEX appoints BIO-RAD as a distributor of (i) LUMINEX100
Systems only as part of BIO-RAD Systems and replacement parts therefor and (ii)
Kits designed solely for use in a Field. Subject to the terms and conditions of
this Agreement, LUMINEX grants to BIO-RAD a personal, nontransferable immunity
from suit under LUMINEX's Intellectual Property Rights, with respect to the re-
sale of Luminex100 Systems as incorporated into BIO-RAD instrumentation and
Kits; provided that Beads are sold only as part of Kits, and further provided
that BIO-RAD Systems and Kits are designed and sold solely for use in the Fields
and subject to the end user customer restrictions set forth in Section 3.6
below. BIO-RAD further agrees not to provide the BIO-RAD Systems to any third
party if BIO-RAD U.S. Diagnostics Division management becomes aware that such
third party has previously used or intends to use (i) the BIO-RAD System with
beads other than the Standard Beads or Magnetic Beads authorized by LUMINEX or
(ii) the BIO-RAD System or Beads outside the Fields. BIO-RAD agrees not to
provide the Luminex100 Systems or BIO-RAD Systems other than in the development
of Kits to be distributed in accordance with this Agreement. LUMINEX agrees to
grant to End User customers of BIO-RAD a license to use Standard Beads and
Magnetic Beads in conjunction with their operation of BIO-RAD Systems pursuant
to the End User Licenses set forth in Section 3.6 below. It is understood and
agreed that except as expressly provided in this Section 3.1 above, no rights or
licenses under LUMINEX's patent rights are granted hereunder nor shall any such
rights or licenses be implied from the terms hereof. The parties further
acknowledge and agree that the covenant not to sue set forth in this Section 3.1
above shall not imply that purchasers of the BIO-RAD System from BIO-RAD obtain
any rights under LUMINEX's patent rights. Rather, LUMINEX will grant End Users
the right under LUMINEX's patent rights to use the Luminex100 System with Kits
pursuant to the End User Licenses described in Section 3.6 below only when such
Kits are purchased by the End User.

     3.2  Exclusivity
          -----------

          (a) During the term hereof, subject to the provisions hereof,
LUMINEX will not, and will not grant to third parties the right to, sell
Kits containing Magnetic Beads for use within the Fields with Luminex100
Systems.

          (b) For a period of three (3) years commencing with first availability
by BIO-RAD of the first Kit in Field four, LUMINEX will not grant to third
parties the right to distribute a Kit incorporating a Panel within Field Four,
which Panel is specifically intended for use in newborn screening; provided that
BIO-RAD shall make the first Kit in Field Four available within three (3) years
of the Effective Date. If BIO-RAD has paid to LUMINEX at least [**] Dollars
($[**]) in royalties with respect to sales of Kits within Field Four during the
period commencing five (5) years after the Effective Date and expiring twelve
months thereafter, LUMINEX will extend the exclusivity period for Field Four for
one (1) additional year. Upon BIO-RAD's request within fifteen days after the
expiration of the foregoing exclusivity period, the parties shall negotiate in
good faith extension of such exclusivity in Field Four for a period of time to
be mutually agreed in writing, which extension shall be subject to minimum
performance obligations to be mutually agreed upon in writing. If the parties do
not agree upon the terms for extension of exclusivity in Field Four within
thirty (30) days after the date of BIO-RAD's request to commence negotiations,
LUMINEX may proceed to grant rights or licenses to third parties with respect to
all or part of Field Four with no further obligation to BIO-RAD. If BIO-RAD
disputes LUMINEX's rights to proceed to grant any such rights or licenses, the
provisions of Section 3.3(b)(ii) shall apply.

---------------
[**] Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.

                                       4
<PAGE>

     3.3  Expansion of Fields.
          -------------------

          (a)  From time to time during the term of this Agreement, if BIO-RAD
requests that one or more of the Fields granted to BIO-RAD be expanded to
include additional analytes, such analytes will be included as part of a Field
presently covered by this Agreement to the extent set forth in Exhibit A, or as
part of an additional field to be licensed or granted to BIO-RAD, in each case
to the extent mutually agreed in writing by the parties. The [**] to BIO-
RAD for each additional analyte or field made generally available for [**] by
LUMINEX on a nonexclusive basis to LUMINEX's customers shall not exceed one [**]
Dollars ($[**]).

          (b)  Preferential Right.

               (i)  Prior to granting to a third party exclusive rights to
develop or distribute Kits for the detection or quantification of one or more
analytes for use within a field within the human clinical diagnostics industry
(such analytes and field of use are referred to collectively herein as the
"Subject Field"), LUMINEX shall provide BIO-RAD with a right of first offer with
respect to such Subject Field, as follows: prior to entering into an agreement
granting a third party exclusive rights to develop and/or distribute Kits within
a Subject Field, LUMINEX shall provide written notification to BIO-RAD, together
with a summary of the Subject Field. Upon request by BIO-RAD within [**]
days after receipt of such a notice, LUMINEX and BIO-RAD shall negotiate in
good faith an agreement with respect to such Subject Field. If BIO-RAD is not
interested in obtaining rights with respect to such Subject Field, BIO-RAD shall
so notify LUMINEX as early as possible during the foregoing [**] day period. If
(i) BIO-RAD does not so request within such [**] day period to commence
negotiations, or notifies LUMINEX that it is not interested in obtaining rights
with respect to such Subject Field, or (ii) the parties do not enter into a
definitive agreement with respect to such Subject Field within [**] days
after BIO-RAD's receipt of LUMINEX's notice under this Section 3.3(b) (in each
of (i) and (ii), the "Negotiation Period"), LUMINEX may proceed to grant rights
or licenses to third parties with respect to all or any part of the Subject
Field, with no further obligation under this Section 3.3. Notwithstanding the
foregoing, BIO-RAD's rights and obligations under this Section 3.3 shall not
apply to a Subject Field for which BIO-RAD does not Control sufficient rights to
commercialize Kits within such Subject Field, where "Control" means ownership or
a license under all applicable intellectual property rights to make, have made,
use, import, sell, offer for sale, and otherwise distribute each Kit within the
Subject Field on a worldwide basis. BIO-RAD's rights and obligations under this
Section 3.3(b) shall terminate [**] years after the Effective Date. For the
avoidance of doubt, it is understood and agreed that LUMINEX shall have no
obligation to disclose to BIO-RAD any information concerning the terms of
LUMINEX's offers to third parties with respect to Subject Fields. It is further
understood and agreed that nothing in this Section 3.3(b) shall restrict LUMINEX
from granting nonexclusive rights to third parties with respect to any analyte
or field of use without any obligation under this Section 3.3(b).

-------------------

[**] Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed seperately with the
Commission pursuant to Rule 406.

                                       5

<PAGE>

                    (ii)   If BIO-RAD disputes LUMINEX'S right to proceed to
grant rights or licenses to third parties with respect to any Subject Field,
BIO-RAD shall request that such dispute be resolved in accordance with Section
12.5 below. If such dispute is not so resolved and BIO-RAD wishes to pursue such
dispute, then prior to ten (10) days after the expiration of the Negotiation
Period described above regarding such Subject Field, or within ten (10) days
after LUMINEX notifies BIO-RAD that LUMINEX believes Section 3.3(b) does not
apply to a Subject Field (as the case may be), BIO-RAD shall submit to LUMINEX a
written notification requesting arbitration pursuant to Section 12.5 below and
including a written report setting forth (without limitation), the specific
basis for the dispute, and the specific actions BIO-RAD believes LUMINEX must
take to resolve the dispute ("Arbitration Notice"). If such Arbitration Notice
is not received within ten (10) days after the expiration of the Negotiation
Period or such ten (10) day period after notice of LUMINEX's belief that this
Section 3.3(b) does not apply (respectively), then notwithstanding Section 12.5
below, BIO-RAD shall have no further right to dispute LUMINEX'S right to grant
any right or license, or otherwise claim rights pursuant to this Section 3.3(b)
in or to the Subject Field. It is further understood that, notwithstanding the
provisions of Section 12.5, the parties and the arbitrators shall complete the
arbitration within sixty (60) days after the appointment of the arbitrators
under Section 12.5. So long as LUMINEX provides to BIO-RAD the notice required
by Section 3.3(b) above, this Section 3.3(b)(ii) is BIO-RAD's sole remedy for
any failure by LUMINEX to comply with this Section 3.3(b) with respect to a
Subject Field.

                    (iii)  It is understood and agreed that a transfer of all or
substantially all of the business or assets of LUMINEX pertaining to the subject
matter of this Agreement to a third party, whether by merger, acquisition or
otherwise, shall not be deemed a grant to a third party of a right or license
with respect to a Subject Field nor give rise to any right or obligation under
Section 3.3(b) above.

     3.4  Reservation of Rights. The use by BIO-RAD of any of LUMINEX's
          ---------------------
Intellectual Property Rights is authorized only for the purposes herein set
forth and upon termination of this Agreement for any reason such authorization
will cease. Nothing in this Agreement (other than Section 3.2 and 3.3(b)) shall
be deemed to restrict LUMINEX's right to exploit the Standard Beads, Magnetic
Beads or Luminex100 Systems. Neither BIO-RAD nor its customers shall receive any
license or rights under LUMINEX's Intellectual Property Rights by virtue of
their purchase of BIO-RAD Systems other than as expressly set forth herein.
Unless otherwise required by applicable law, BIO-RAD shall not remove, alter,
cover or obfuscate any patent markings, copyright notices or other proprietary
rights notices placed on or embedded in the Standard Beads, Magnetic Beads,
Software or Luminex100 Systems. BIO-RAD shall mark all Kits and BIO-RAD Systems
sold or otherwise distributed under this Agreement in accordance with the
applicable statutes and regulations relating to patent marking of the United
States and all other countries in which the Kits or BIO-RAD Systems are made or
sold. LUMINEX will provide copies in writing of the patents to be covered by
such notice and hereby warrants the accuracy of and right to use such notices.

     3.5  No Right to Manufacture or Modify.  Software is licensed, and Beads
          ---------------------------------
and non-Software portions of the Luminex100 System are sold subject in every
case to the condition that such transfer does not convey any license, expressly
or by implication, to manufacture, reconstruct, modify, duplicate or otherwise
copy or reproduce any of the Beads, Software or the Luminex100 Systems. BIO-RAD
shall not alter, modify, adapt, translate, prepare derivative works from,
decompile, reverse engineer, disassemble, or attempt to derive computer source
code from any Luminex100 System or Software. BIO-RAD will notify LUMINEX
immediately upon BIO-RAD U.S. Diagnostics Division management becoming aware
that BIO-RAD or any third party has engaged in any of the foregoing activities
and shall cease selling BIO-RAD Systems or Beads to any such person or entity.
BIO-RAD further agrees that the Standard Beads or Magnetic Beads and Luminex100
System comprise a single system, and the Luminex100 System may not be used by
BIO-RAD with beads other than the Standard Beads or Magnetic Beads authorized by
LUMINEX.

     3.6  End User License.  BIO-RAD shall include a copy of the End User Kit
          ----------------
and Software license agreements attached hereto as Exhibit B (the "End User
Licenses") with each Kit or BIO-RAD System, respectively, shipped to a customer
by or for BIO-RAD.  BIO-RAD shall further include the labels set forth in
Exhibit B on every BIO-RAD System and Kit.

                                       6
<PAGE>

     3.7  Subdistributors.  Subject to all the terms and conditions herein,
          ---------------
BIO-RAD may appoint third parties within BIO-RAD's normal chain of distribution
to sell Kits in accordance with the provisions of this Article 3 and may appoint
subdistributors within its normal chain of distribution to distribute BIO-RAD
Systems (such subdistributors are referred to collectively herein as
"Subdistributors"); provided that (i) BIO-RAD shall terminate any such
Subdistributor that does not follow the provisions of Article 1 (to the extent
referenced in the following Sections), 3, and 7 and Sections 4.5, 4.13, 5.3,
8.1, 8.4, 8.5, 12.1, 12.3, 12.9, and 12.15 of this Agreement, and (ii) BIO-RAD
shall diligently enforce all such Subdistributor agreements. For the avoidance
of doubt, in no event shall BIO-RAD provide Standard Beads or Magnetic Beads to
third parties except as incorporated into Kits or as replacement components of
Kits. Except as expressly provided in this Section 3.7, BIO-RAD shall have no
right to sublicense its rights or appoint Subdistributors hereunder.

     3.8  To LUMINEX.  BIO-RAD hereby grants to LUMINEX a nonexclusive,
          ----------
worldwide, unrestricted license, with the right to grant and authorize
sublicenses, under BIO-RAD Improvement Patents solely for use with Luminex100
Systems and Beads and only for use outside of any Fields granted exclusively to
BIO-RAD. Such license shall be deemed royalty-free and fully-paid up.

                                   ARTICLE 4
                         SUPPLY, PRICING AND ROYALTIES
                         -----------------------------

     4.1  Supply and Use of Standard Beads and Luminex100 Systems.  Subject to
          -------------------------------------------------------
the terms and conditions of this Agreement, BIO-RAD agrees to acquire from
LUMINEX, and LUMINEX agrees to use reasonable, diligent efforts to supply to
BIO-RAD, BIO-RAD's commercial requirements of Standard Beads and Luminex100
Systems. To ensure the quality and authenticity of the microsphere beads used
with the Luminex100 System, BIO-RAD shall exclusively obtain from LUMINEX
fluorescently-dyed microsphere beads for use with the Luminex100 System, or with
respect to microsphere beads with magnetic properties, have such magnetic beads
dyed and processed by LUMINEX for use with the Luminex100 System.

     4.2  Forecasts.  Within ten (10) days prior to each calendar quarter,
          ---------
BIO-RAD and LUMINEX shall agree in writing upon a rolling six month forecast of
delivery requirements of Standard Beads and Luminex100 Systems in each
respective month ("Forecast"). Within ten days following the Effective Date, the
parties shall agree in writing upon the Forecast for the six month period
commencing on March 1, 1999. The first ninety (90) days of the Forecast shall be
binding upon each of the parties hereto. Except as set forth in this Section 4.2
above, The Forecasts shall constitute BIO-RAD's good faith estimates of BIO-
RAD's requirements, and otherwise shall be nonbinding upon either party.

     4.3  Orders.  LUMINEX shall accept purchase orders from BIO-RAD for
          ------
Standard Beads and Luminex100 Systems to the extent the volume of Luminex100
Systems is within one hundred thirty percent (130%) of the Forecasts submitted
by BIO-RAD in the calendar month preceding the submission of the purchase order,
and to the extent the volume of Standard Beads is within one hundred fifty
percent (150%) of the Forecasts submitted by BIO-RAD in the calendar month
preceding the submission of the purchase order, in all events subject to the
other terms and conditions of this Agreement. BIO-RAD's orders shall be made
pursuant to written firm purchase orders, and shall provide for shipment in
accordance with LUMINEX's standard lead times then in effect which as of the
Effective Date are ninety (90) days. ANY ADDITIONAL OR INCONSISTENT TERMS OR
CONDITIONS OF ANY PURCHASE ORDER, ACKNOWLEDGMENT OR SIMILAR STANDARDIZED FORM
GIVEN OR RECEIVED PURSUANT TO THIS AGREEMENT SHALL HAVE NO EFFECT AND SUCH TERMS
AND CONDITIONS ARE HEREBY EXCLUDED.

     4.4  Delivery.  With respect to exact shipping dates, LUMINEX shall use its
          --------
reasonable efforts to ship quantities of Standard Beads and Luminex100 Systems
in accordance with purchase orders submitted and accepted in accordance with
Section 4.3 above. All Beads and Luminex100 Systems supplied pursuant to the
terms of this Agreement shall be suitably packed for shipment by LUMINEX and
marked for shipment to the BIO-RAD facility indicated in BIO-RAD's purchase
order. All Beads and Luminex100 Systems will be shipped F.O.B. (U.C.C.) the

                                       7
<PAGE>

shipping point designated by LUMINEX. The carrier shall be selected by agreement
between LUMINEX and BIO-RAD, provided that in the event no such agreement is
reached, LUMINEX shall select the carrier. All shipping and insurance costs, as
well as any special packaging expenses, shall be paid by BIO-RAD.

     4.5  Acceptance.  All shipments and all shipping and other charges shall be
          ----------
deemed correct unless LUMINEX receives from BIO-RAD, no later than thirty (30)
days after BIO-RAD's receipt of a given shipment, a written notice specifying
the shipment, the purchase order number, and the nature of the discrepancy
between the order and the shipment or the nature of the discrepancy in the
shipping or other charges, as applicable. LUMINEX agrees to replace, at no
additional expense to BIO-RAD, any Standard Beads or Luminex100 Systems which
fail to conform to the Bead Specifications or Luminex100 System Specifications,
respectively, with Standard Beads or Luminex100 Systems which conform to the
Bead Specifications or Luminex100 System Specifications, respectively. LUMINEX
may analyze any Standard Beads or Luminex100 Systems rejected by BIO-RAD for
nonconformity and if it is objectively established that the Standard Beads or
Luminex100 Systems were conforming, then BIO-RAD shall be responsible for
payment for such Standard Beads or Luminex100 Systems. BIO-RAD shall, at
LUMINEX's option, return to LUMINEX or destroy, and provide written
certification of destruction, all Standard Beads which do not conform to the
Bead Specifications, and BIO-RAD shall return to LUMINEX all Luminex100 Systems
which do not conform to the Luminex100 System Specifications. All returns shall
be in accordance with LUMINEX's written instructions and shall be at LUMINEX's
expense if the Luminex100 System and/or Standard Beads are confirmed by LUMINEX
as defective in Luminex's reasonable judgment.

     4.6  Pricing and Royalties.
          ---------------------

          (a)  Standard Bead Pricing. BIO-RAD shall pay to LUMINEX [**]
               ---------------------
[$**] for every [**] units of Standard Beads purchased, where a "unit" of
Standard Beads is equal to one microsphere bead ("Unit Transfer Fee"). This Unit
Transfer Fee will be effective during the first [**] years of this Agreement,
after which time LUMINEX may, at its option, increase the Unit Transfer Fee
effective on [**] days written notice to BIO-RAD. Such increases may occur no
more frequently than once per year. Each annual increase during the first [**]
years after commercial availability of the first Kit shall not exceed [**]
percent ([**]%) of the Unit Transfer Fee previously in effect and thereafter
shall not exceed the [**]. Any increase in the Unit Transfer Fee shall be
effective for all Standard Beads ordered after such notice. Without limiting the
foregoing, the parties agree to negotiate an equitable adjustment to the fees
for Standard Beads in the event of an increase in LUMINEX's cost of Standard
Beads or components thereof purchased from a third party supplier.

          (b)  Magnetic Bead Tolling Fee.  BIO-RAD shall pay to LUMINEX a
               -------------------------
tolling fee with respect to each dyed Magnetic Bead. The amount of the tolling
fee shall be set forth in the Development Agreement (as defined in
Section 2.1(d) above).

          (c)  Kit Royalties. BIO-RAD shall pay to LUMINEX [**] percent ([**]%)
               -------------
of Net Sales for Kits sold by BIO-RAD. With respect to BIO-RAD Systems that are
sold on a reagent rental basis, "Net Sales" shall exclude the purchase price of
the instrumentation, fees received for servicing the instrumentation and the
cost of financing the instrumentation, provided that the cost of financing the
instrumentation shall not exceed [**] percent ([**]%) of the purchase price of
the instrumentation ("Kit Royalty"). Notwithstanding the foregoing, if at the
time of the sale of the Kit by BIO-RAD to a third party, LUMINEX charges a third
party distributor of Kits a royalty for Kits sold of less than [**] percent
([**]%) of Net Sales and also charges such third party distributor a transfer
price for the Standard Beads that equals or exceeds the Unit Transfer Fee set
forth in Section 4.6(a) above under an agreement for distribution of in vitro
                                                                     --------
diagnostic Kits, LUMINEX will offer such lower Kit Royalty to BIO-RAD.

          (d)  Combination Sales.  In the event that a Kit is sold by BIO-RAD in
               -----------------
combination with another test not for the Luminex100 System and is priced as a
single combined unit, the portion of Net Sales attributable

---------------
[**]  Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.

                                       8
<PAGE>

to the Kit shall be calculated by multiplying the total net sales for the
combination by the fraction A/B, where "A" is BIO-RAD list price for the Kit and
"B" is the sum of BIO-RAD list price for the Kit and BIO-RAD list prices of the
other products sold in combination with the Kit. If BIO-RAD does not have a
separate list price for the Kit or such other products, BIO-RAD and LUMINEX
agree to negotiate in good faith a reasonable allocation.

     (e)  Advance Against Royalties.  Upon the Effective Date, BIO-RAD shall
          -------------------------
pay to LUMINEX [**] Dollars ($[**]) for each of Field One, Field Two, Field
Three and Field Four (i.e., a total of [**] Dollars ($[**])) as an advance
against Kit Royalties ("Advance"), which Advance shall be fully creditable
against Kit Royalties earned during the first [**] years of this Agreement. The
parties will discuss and agree upon any Advance owed by BIO-RAD for fields in
addition to the Fields prior to adding the additional field. To the extent BIO-
RAD does not generate Kit Royalties equal to or in excess of the Advance during
such [**] year period, the remainder of the Advance not credited against Kit
Royalties shall be deemed nonrefundable.

     (f)  Luminex100 System Pricing.  BIO-RAD shall pay LUMINEX (i) the amounts
          -------------------------
set forth in Exhibit E hereto for each Luminex100 System (excluding off-the-
shelf computer components) and (ii) LUMINEX's cost plus [**] percent ([**]%) for
off-the-shelf computer components if purchased from LUMINEX (collectively, the
"Luminex100 Purchase Price"). [**]. The parties understand that BIO-RAD is not
required to purchase off-the-shelf computer components from LUMINEX, and may
source the same directly from the manufacturer, provided that the Luminex100
System is intended for use only on those brands and configurations of computers
supported by LUMINEX, the complete list of which, together with all updates,
LUMINEX shall provide to BIO-RAD. Use with any off-the-shelf computer components
other than those set forth on said list shall result in the voiding of all
warranties provided by LUMINEX to BIO-RAD hereunder except for any warranty
given by LUMINEX hereunder regarding intellectual property; provided, however,
that if the unlisted off-the-shelf computer components give rise to a claim of
infringement of a third party intellectual property right which infringement
would not have arisen had a listed off-the-shelf computer component been used,
such infringement shall be excluded from any intellectual property warranty or
indemnity provided hereunder.

     4.7  Conflicts of Interest.  It is understood and agreed that BIO-RAD may
          ---------------------
sell the Kits or sell BIO-RAD Systems to End Users or Subdistributors who
purchase other products and services of BIO-RAD, and as a result, a conflict of
interest may arise. BIO-RAD agrees that BIO-RAD shall not put into place a
specific marketing, promotional or pricing plan which shall discount kits in
order to achieve higher sales of, or a higher sales price for, another product
or service of BIO-RAD. BIO-RAD further agrees that BIO-RAD will not bundle the
Kits or the Luminex100 Systems in a manner that would disadvantage the Kits or
the Luminex100 Systems in comparison with such other products or services
marketed by BIO-RAD.

     4.8  Invoicing.  LUMINEX shall submit an invoice to BIO-RAD upon shipment
          ---------
of Standard Beads or Luminex100 Systems ordered by BIO-RAD hereunder. All
invoices shall be sent to the following address: Bio-Rad Laboratories, Inc.,
Accounts Payable, 4000 Alfred Nobel Drive, Hercules, California 94547, or such
other address as specified in the purchase order therefor, and each such invoice
shall state the fees due for Standard Beads or Luminex100 Systems in a given
shipment, plus any insurance, taxes incident to the purchase or shipment
initially paid by LUMINEX but to be borne by BIO-RAD hereunder.

     4.9  Reporting and Payment.  Payment of the Unit Transfer Fee and the
          ---------------------
Luminex100 Purchase Price shall be made within thirty (30) days of BIO-RAD's
receipt of an invoice therefor. Payment of Kit Royalties shall be made within
the first ten days of each calendar month for Net Sales in the calendar month
two months prior to the calendar month in which payment is made (e.g., the Kit
Royalties payable within the first ten days of June will be based on Net Sales
in April). Kit Royalties shall be accompanied by a written report stating the
Net Sales generated

--------------
[**]   Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.

                                       9
<PAGE>

in the calendar month to which the payment pertains and the total Kit Royalties
due. All payments hereunder shall be made in U.S. dollars, by direct bank
transfer to an account designated in LUMINEX's invoice. Any late payments shall
bear interest at the rate of one and one-half percent (1 1/2 %) per month or the
highest rate under applicable law, which ever is less, based on the number of
days overdue.

     4.10 Taxes.
          -----

          (a)  Any and all amounts payable hereunder do not include any
government taxes (including without limitation sales, use, excise, and value
added taxes) or duties imposed by any governmental agency that are applicable to
the export, import, or purchase of the Standard Beads or the Luminex100 System
(other than taxes on the net income of LUMINEX), and BIO-RAD shall bear all such
taxes and duties. When LUMINEX has the legal obligation to collect and/or pay
such taxes, the appropriate amount shall be added to BIO-RAD's invoice and paid
by BIO-RAD, unless BIO-RAD provides LUMINEX with a valid tax exemption
certificate authorized by the appropriate taxing authority.

          (b)  All payments by BIO-RAD specified hereunder are expressed as net
amounts and shall be made free and clear of, and without reduction for, any
withholding taxes. Any such taxes which are otherwise imposed on payments to
LUMINEX shall be the sole responsibility of BIO-RAD. BIO-RAD shall provide
LUMINEX with official receipts issued by the appropriate taxing authority or
such other evidence as is reasonably requested by LUMINEX to establish that such
taxes have been paid. If LUMINEX uses a foreign tax credit received by LUMINEX
as a result of the payment of withholding taxes by BIO-RAD and thereby reduces
the amount of U.S. income tax that LUMINEX otherwise would have paid, LUMINEX
shall refund to BIO-RAD the amount of such reduction with respect to such
foreign tax credit. LUMINEX will use commercially reasonable efforts to obtain
foreign tax credits to which LUMINEX is entitled.

     4.11 Improvements to Standard Beads or Luminex100 System.  If during the
          ---------------------------------------------------
term of this Agreement LUMINEX enters into a royalty-bearing license or
agreement or a license or agreement requiring payment of license fees or other
payments for the license or other acquisition of rights to new technologies
applicable to the manufacture, sale or use of the Standard Beads or Luminex100
System, and after consultation with BIO-RAD, BIO-RAD does not agree to pay any
such amounts applicable to the manufacture, sale or use of the Standard Beads or
Luminex100 System, within thirty (30) days after a written request by LUMINEX,
LUMINEX at its option may exclude from this Agreement the subject matter covered
by such license or agreement, and in such event the same shall not be within the
Standard Beads or Luminex100 System for any purposes of this Agreement. The
provisions of this Section 4.11 shall not limit the obligations of the parties
under Article 11.

          (a)  At the Effective Date, to the knowledge of LUMINEX's senior
management, LUMINEX is not engaged in negotiations to obtain rights to royalty-
bearing technologies to which this Section 4.11 pertains.

          (b)  LUMINEX represents and warrants to BIO-RAD that it has not, up
through and including the date of this Agreement, received from any third party
any information about or notice of any claim or infringement with respect to or
affecting the validity or enforceability of any of the patents, copyrights,
trademarks or know-how relating to the Standard Beads or the Luminex100 System
or any portions thereof.

     4.12 Currency Conversion.  If any currency conversion shall be required in
          -------------------
connection with the calculation of amounts payable under this Agreement, such
conversion shall be made using the selling exchange rate for conversion of the
foreign currency into U.S. Dollars, quoted for current transactions reported by
the Wall Street Journal (New York Edition) for the last business day of the
calendar period to which such payment pertains.

     4.13 BIO-RAD Records; Inspection.  BIO-RAD shall keep complete, true and
          ---------------------------
accurate books of accounts and records for the purpose of determining the
amounts payable under this Article 4 or verifying compliance with Section 8.1.
Such books and records shall be kept for at least three (3) years following the
end of the calendar quarter to which they pertain. Such records will be open for
inspection during such three (3)-year period by an independent

                                       10
<PAGE>

auditor chosen by LUMINEX at BIO-RAD's site for the purpose of verifying the
amounts payable by BIO-RAD under this Article 4 or compliance with Section 8.1.
Such on-site inspections may be made no more than once each calendar year, at
reasonable times and on reasonable notice. LUMINEX's auditor will only be
required to reveal whether correct payment was made and if not, the amount of
the underpayment or overpayment. The auditor will be subject to reasonable
confidentialty restrictions with respect to information learned in the course of
performing the audit. Inspections conducted under this Section 4.13 shall be at
the expense of LUMINEX, unless a variation or error producing an underpayment in
amounts payable exceeding five percent (5%) of the amount paid for any period
covered by the inspection is established in the course of any such inspection,
whereupon all costs relating to the inspection for such period and any unpaid
amounts that are discovered shall be paid by BIO-RAD, together with interest as
specified in Section 4.9 above. The parties will endeavor to minimize disruption
of BIO-RAD's normal business activities to the extent reasonably practicable.

     4.14 LUMINEX Records; Inspection. LUMINEX shall keep complete, true and
          ---------------------------
accurate books of accounts and records for the purpose of verifying its
compliance with the pricing provisions of Section 4.6(b) and 4.6(e). Such books
and records shall be kept for at least three (3) years following the end of the
calendar quarter to which they pertain. Such records will be open for inspection
during such three (3)-year period by an independent auditor chosen by BIO-RAD,
at LUMINEX's site for the sole purpose of verifying LUMINEX's compliance with
the pricing provisions of Section 4.6(c) and 4.6(e). Such on-site inspections
may be made no more than once each calendar year, at reasonable times and on
reasonable notice. BIO-RAD's auditor will only be required to reveal whether
correct invoicing was made and if not, the amount of the overpayment. The
auditor will be subject to reasonable confidentialty restrictions with respect
to information learned in the course of performing the audit. Inspections
conducted under this Section 4.14 shall be at the expense of BIO-RAD unless a
variation or error producing an overpayment in amounts payable exceeding five
percent (5%) of the amount paid for any period covered by the inspection is
established in the course of any such inspection, whereupon all costs relating
to the inspection for such period and any unpaid amounts that are discovered
shall be paid by LUMINEX, together with interest at the rate specified in
Section 4.9 above. The parties will endeavor to minimize disruption of LUMINEX's
normal business activities to the extent reasonably practicable.

     4.15 Late Delivery Charges.  If LUMINEX fails to deliver Standard Beads in
          ---------------------
accordance with the requirements of Section 4.3 and 4.4, LUMINEX shall deduct
from invoices submitted to BIO-RAD the following percentage of the sales price
of the Standard Beads:

     Days of LUMINEX Delay    Percentage of Invoiced Sales Price of Standard
     ---------------------    ----------------------------------------------
                              Beads
                              -----

     [**]                     [**]%

     [**]                     [**]%

     [**]                     [**]%

     [**]                     [**]%

If LUMINEX fails to deliver Luminex100 Systems in accordance with the
requirements of Section 4.3 and 4.4, LUMINEX shall deduct from invoices
submitted to BIO-RAD the following percentage of the sales price of the
Luminex100 System (excluding off-the-shelf computer components):

------------
[**] Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.

                                       11
<PAGE>

<TABLE>
<CAPTION>
     Days of LUMINEX Delay    Percentage of Invoiced Sales Price of Luminex100 System
     --------------------     -------------------------------------------------------
<S>                           <C>
     [**]                     [**]%

     [**]                     [**]%

     [**]                     [**]%

     [**]                     [**]%
</TABLE>

     4.16  Manufacturing Capacity.
           ----------------------

           (a)  Back-Up Manufacturing Right. A "Supply Failure" shall mean a
                ---------------------------
failure, in any [**] calendar quarters within any [**] month period, in each
case beginning at least [**] months after BIO-RAD's first commercial sale of a
BIO-RAD System, to supply BIO-RAD with at least seventy-five percent (75%) of
the aggregate quantity of Standard Beads or Luminex100 Systems, as applicable,
ordered pursuant to Section 4.3 by BIO-RAD for such two calendar quarters. In
the event of a Supply Failure, BIO-RAD shall have a back-up supply right as set
forth below (the "Back-Up Right") subject to the additional terms and conditions
set forth below or in the Escrow Agreement (as identified below).

           (b) Escrow. The parties will enter into an escrow agreement (the
               ------
"Escrow Agreement") within thirty (30) days of the execution of this Agreement.
LUMINEX agrees to deposit, subject to Section 4.16(c) below, in the technology
escrow account with a third party escrow agent all technical information, know-
how, supplier lists, bill of materials and related information covering Standard
Beads and Luminex100 Systems that is owned or controlled by LUMINEX and is
necessary for the manufacture of Standard Beads and Luminex100 Systems but in
all events excluding Software source code (the "Escrowed Materials"). For
purposes of this Section 4.13(b), "control" means the ability to grant the
rights set forth in Section 4.13(c) without payment of royalties or other
consideration to third parties or any other restrictions from third parties that
would interfere with BIO-RAD's rights to use the Escrowed Materials. The
Escrowed Materials are to be released to BIO-RAD in the event of a Supply
Failure, all as to be specified in more detail in the Escrow Agreement.

          (c)  Rights. Upon the occurrence of a Supply Failure with respect to
               ------
Standard Beads or Luminex100 Systems, the immunity from suit granted under
Section 3.1 shall include the right to manufacture Standard Beads or Luminex100
Systems, respectively, and, at BIO-RAD's option, BIO-RAD may manufacture or have
manufactured, BIO-RAD's requirements for Standard Beads or Luminex100 Systems,
respectively, at royalty rates to be negotiated in good faith by the parties. If
the parties have failed to agree upon the royalty rates for Standard Beads
and/or Luminex100 Systems within two calendar months of BIO-RAD's exercise of
its option to manufacture or have manufactured the Standard Beads and/or
Luminex100 Systems, the parties shall submit the matter of determining a
commercially reasonable royalty with respect to the manufacture and sale of
Standard Beads and/or Luminex100 Systems to arbitration pursuant to Section
12.5. The arbitrator shall be instructed to take into consideration BIO-RAD's
Cost of Goods with respect to the manufacture of the Standard Beads and/or
Luminex100 Systems, where "Cost of Goods" means cost of direct labor, direct
materials and manufacturing overhead incurred in the manufacturing of Standard
Beads and/or Luminex100 Systems as calculated in accordance with U.S. GAAP and
consistent with the methods used by BIO-RAD to calculate direct and indirect
costs for its other product lines, excluding sales, general and administrative
costs (SG&A). In the event that BIO-RAD elects to exercise this option with
respect to Standard Beads or Luminex100 Systems, LUMINEX shall have no further
obligation to supply Standard Beads or Luminex100 Systems, as applicable, to
BIO-RAD and LUMINEX's obligations under Article 7 shall cease. In the event that
LUMINEX cures its Supply Failure, LUMINEX may terminate the rights provided to
BIO-RAD under this Section 4.16 upon one hundred twenty (120) days written
notice to BIO-RAD.

------------
[**] Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.

                                       12
<PAGE>

     4.17  THE PROVISIONS OF SECTION 4.15 SETS FORTH THE SOLE AND EXCLUSIVE
REMEDY FOR ANY FAILURE BY LUMINEX TO SUPPLY BEADS OR LUMINEX100 SYSTEMS.

                                   ARTICLE 5
                                   ---------
                            REGISTRATION CODE FEE,
                            ----------------------
                  EXCLUSIVITY OF EFFORTS AND OTHER PROVISIONS
                  -------------------------------------------

     5.1  Registration Code Fee. LUMINEX will designate one (1) Registration
          ---------------------
Code for each Test with respect to which a Kit may be used, and BIO-RAD agrees
that Standard Beads supplied to BIO-RAD hereunder will include Standard Beads
containing such Registration Codes. BIO-RAD shall pay to LUMINEX Three Hundred
Fifty Dollars ($350) per analyte in a given Test which the Registration Code is
designed to detect; provided that the fee for any given Panel shall not exceed
Five Thousand Dollars ($5,000). With respect to Registration Codes designated as
of the Effective Date, such amounts shall be due and payable on the Effective
Date; with respect to Registration Codes later designated such amounts shall be
due at the time of designation by LUMINEX.

     5.2  Exclusivity of Efforts. To avoid conflicts of interest, BIO-RAD and
          ----------------------
its Affiliates will not manufacture, market, sell or otherwise distribute any
materials, technologies or products, other than Luminex100 System and Kits,
specifically designed for performing Multiplexed Bead Assays using flow
cytometry based detection of particles for use in the human clinical diagnostics
industry within the Field. In addition, BIO-RAD agrees that except for
performing its development obligations as agreed pursuant to Section 2.1, BIO-
RAD's clinical diagnostics division or group will not directly or indirectly
develop any materials, technologies or products specifically designed for
performing Multiplexed Bead Assays within the Fields using flow cytometry based
detection of particles. BIO-RAD further agrees that it will not provide research
and development funding to or license any third party to develop, manufacture,
market, sell or otherwise distribute any materials, technologies or products
specifically designed for performing Multiplexed Bead Assays within the Fields
using flow cytometry based detection of particles. It is understood that the
foregoing sentence shall not apply to passive investments by BIO-RAD in equity
of third parties for use in the human clinical diagnostics industry.

     5.3  Compliance with Laws. Each party shall be responsible for complying in
          --------------------
all material respects with all directives, laws, rules and regulations relating
to the performance of such party's obligations and exercise of such party's
rights hereunder, including without limitation regulatory reporting regulations.
BIO-RAD further shall be responsible for all activities relating to recalls.

     5.4  Luminex100 Systems. In addition to the terms and conditions of this
          ------------------
Agreement, sale of the Luminex100 System shall be subject to LUMINEX's standard
terms and conditions for labelling and patent marking.

                                   ARTICLE 6
                       MAINTENANCE, SUPPORT AND TRAINING
                       ---------------------------------

     6.1  Maintenance and Support. BIO-RAD will provide front-line maintenance
          -----------------------
and support for each Luminex100 System purchased by BIO-RAD. The scope of
maintenance and support services provided by LUMINEX will be limited to the
provision of Updates and LUMINEX's standard telephone hotline support to the
extent that LUMINEX makes such telephone support available generally to its
customers free of charge. LUMINEX shall not be responsible for problems arising
in whole or in part from portions of the BIO-RAD System other than the
Luminex100 System as delivered by LUMINEX, as determined by LUMINEX in LUMINEX's
sole reasonable discretion.

     6.2  Training. At BIO-RAD's request, LUMINEX will provide three (3) days a
          --------
year of training for BIO-RAD field technicians at LUMINEX's facility. BIO-RAD
will be responsible for all travel, food and lodging expenses incurred by BIO-
RAD in connection with such training.

                                       13
<PAGE>

                                   ARTICLE 7
                               LIMITED WARRANTY
                               ----------------

     LUMINEX makes the warranties set forth in Exhibit C to BIO-RAD. BIO-RAD
agrees not to represent the Standard Beads or Luminex100 System in a manner that
is inconsistent with the Specifications or otherwise misrepresent the Standard
Beads or Luminex100 System. EXCEPT AS EXPRESSLY PROVIDED IN EXHIBIT C, LUMINEX
MAKES NO WARRANTIES OR CONDITIONS (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE)
WITH RESPECT TO THE SUBJECT MATTER HEREOF, AND LUMINEX SPECIFICALLY DISCLAIMS
ANY AND ALL IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY AND FITNESS FOR
A PARTICULAR PURPOSE.

                                   ARTICLE 8
                             TERM AND TERMINATION
                             --------------------

     8.1  Term. The term of this Agreement shall commence on the Effective Date
          ----
and continue in full force and effect for a period of seven (7) years after the
first commercial sale of a Kit by BIO-RAD ("Initial Term"), unless earlier
terminated in accordance with this Agreement. This Agreement shall be
automatically extended for additional two (2) year terms for up to three (3)
renewal terms; provided, however, that in the event BIO-RAD does not demonstrate
a significant investment in the research and development of the BIO-RAD System
in excess of [**] Dollars ($[**]) by the expiration of the Initial Term, LUMINEX
may terminate this Agreement by a written notice of termination to BIO-RAD at
least ninety (90) days prior to the expiration of the Initial Term; and further
provided that the automatic renewal of the term of this Agreement for each of
the foregoing two year renewal terms after the first renewal term shall be
subject to the parties agreeing upon and BIO-RAD meeting annual sales goals with
respect to BIO-RAD Systems and Kits which annual sales goals shall be negotiated
in good faith by the parties prior to the commencement of each such renewal
term.

     8.2  Termination for Breach. This Agreement may be terminated by either
          ----------------------
party by written notice effective immediately if the other party breaches any
material term or condition of this Agreement and fails to remedy the breach
within thirty (30) days after being given written notice thereof stating the
nonbreaching party's intent to terminate. Without limiting the foregoing, either
party may terminate portions of this Agreement pursuant to Section 12.14.

     8.3  Termination for Failure to Commercialize. Beginning [**] years
          ----------------------------------------
after availability of the Luminex100 System, if at any time BIO-RAD is not
marketing, selling or distributing one or more Kits for an application within
each of the Fields, LUMINEX may terminate the Agreement with respect to those
Fields in which BIO-RAD is not marketing, selling or distributing by written
notice to BIO-RAD. In the event of such termination under this Section 8.3, the
Advance shall become non-refundable. If BIO-RAD has not made commercially
available Kits incorporating Magnetic Beads in each of the Fields within [**]
years of the Effective Date plus any extension of time necessary to produce
Magnetic Beads reasonably acceptable to BIO-RAD, LUMINEX may terminate [**] by
written notice to BIO-RAD.

     8.4  Effect of Termination. BIO-RAD may sell BIO-RAD Systems existing in
          ---------------------
its inventory as of the effective date of termination of this Agreement, and
procure LUMINEX 100 Systems for orders for BIO-RAD Systems existing as of the
effective date of termination, for a period of ninety (90) days after the
effective date of such termination. LUMINEX agrees to supply Standard Beads to
BIO-RAD and/or to process Magnetic Beads for a period of five (5) years after
any termination or expiration of this Agreement other than termination by
LUMINEX pursuant to Section 8.2. The parties agree to negotiate in good faith an
extension of such commitment after the expiration of such five (5) year period.

     8.5  Return of Materials. Within thirty (30) days after the effective date
          -------------------
of termination of this Agreement, BIO-RAD shall at LUMINEX's option destroy
LUMINEX's Confidential Information provided to BIO-RAD, and provide written
certification of such destruction, or prepare such LUMINEX Confidential
Information for shipment

------------
[**] Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.

                                       14
<PAGE>

to LUMINEX or LUMINEX's designee, as LUMINEX may direct, at LUMINEX's expense.
BIO-RAD shall not make or retain any copies of any LUMINEX Confidential
Information which may have been entrusted to it except for one (1) archival
copy.

     8.6  Survival. It is understood that termination of this Agreement shall
          --------
not relieve a party from any liability which, at the time of such termination,
has already accrued to the other party. The provisions of Sections 3.1, 3.5,
3.6, 3.7, 4.1, the first sentence of 4.2, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 4.10,
4.11, 4.12, 4.13, 4.14 and 4.15 and the last sentence of Section 4.3 hereof
shall survive with respect to Beads supplied during the five year period set
forth in Section 8.4. In addition, the following provisions shall survive any
expiration or termination of this Agreement: Articles 6, 7, 9, 10 (for a period
of five years after expiration of the period set forth in Section 8.4), 11, and
12, and Sections 3.4, 3.5, 3.6, 3.8, 4.10, 4.13, 5.3, 8.4, 8.5, and 8.6. Except
as otherwise expressly provided in this Article 8, all other rights and
obligations of the parties shall terminate upon termination of this Agreement.
End User Licenses shall survive expiration or termination of this Agreement.

                                   ARTICLE 9
                              LUMINEX TRADEMARKS
                              ------------------

     9.1  Trademarks.  All BIO-RAD Systems, Luminex100 Systems and Kits will be
          ----------
branded with LUMINEX's Trademarks in a manner to be mutually agreed upon in
writing. Subject to the provisions of this Article 9, during the term of this
Agreement, BIO-RAD shall have the right to indicate to the public that the Kits
contain Standard Beads or Magnetic Beads, and to advertise the Standard Beads or
Magnetic Beads as incorporated into the Kits under the trademarks, marks, and
trade names of LUMINEX set forth in Exhibit D, as same may be amended in writing
by LUMINEX from time to time ("LUMINEX's Trademarks"), subject to LUMINEX's
prior inspection and written approval of the Kits, BIO-RAD Systems and
Luminex100 Systems in which the LUMINEX Trademarks are attached. In addition,
BIO-RAD shall affix and display LUMINEX's Trademarks, which may be subordinate
to BIO-RAD's product trademark or trademarks, on the external casing, packaging
and labeling of Kits in a manner approved in writing by LUMINEX. All
representations of LUMINEX's Trademarks that BIO-RAD intends to use shall first
be submitted to LUMINEX for approval (which shall not be unreasonably withheld)
of design, color and other details, or shall be exact copies of those used by
LUMINEX. BIO-RAD shall fully comply with all guidelines, if any, communicated by
LUMINEX concerning the use of LUMINEX's Trademarks. LUMINEX may modify any
LUMINEX Trademarks, or substitute an alternative mark for any LUMINEX Trademark
upon sixty (60) days prior notice to BIO-RAD; provided that BIO-RAD shall not be
obligated to modify catalogs until the next scheduled update to the catalog
unless LUMINEX pays the incremental cost of making the modification in advance
of the next scheduled release. BIO-RAD shall not incur any such incremental cost
without LUMINEX's prior written approval of such cost.

     9.2  Use. Except as otherwise expressly agreed in writing, BIO-RAD shall
          ---
not alter or remove any of LUMINEX's Trademarks affixed to or otherwise
contained on or within the Luminex100 System. Except as set forth in this
Article 9, nothing contained in this Agreement shall grant or shall be deemed to
grant to BIO-RAD any right, title or interest in or to LUMINEX's Trademarks. All
uses of LUMINEX's Trademarks will inure solely to LUMINEX, BIO-RAD shall obtain
no rights with respect to any of LUMINEX's Trademarks, other than as expressly
set forth herein, and BIO-RAD irrevocably assigns to LUMINEX all such right,
title and interest, if any, in any of LUMINEX's Trademarks. At no time during
the term of this Agreement or the period of supply set forth in Section 8.4
shall BIO-RAD challenge or assist others to challenge the No Challenge
Trademarks (except to the extent expressly required by applicable law) or the
registration thereof or attempt to register any trademarks, marks or trade names
confusingly similar to the No Challenge Trademarks. For purposes of this Section
9.2, "No Challenge Trademarks" shall mean the marks listed on Exhibit D at the
Effective Date and such other marks as Luminex adds to Exhibit D pursuant to
Section 9.1, provided that the inclusion of such additional marks within the
definition of No Challenge Marks shall be subject to the approval of BIO-RAD
which approval shall not be unreasonably withheld. Upon termination of this
Agreement, BIO-RAD shall immediately cease to use all LUMINEX's Trademarks and
any listing by BIO-RAD of LUMINEX's name in any telephone book, directory,
public record or elsewhere, shall be removed by BIO-RAD as soon as possible, but
in any event not later than the subsequent issue of such publication;

                                       15
<PAGE>

provided, however, that the foregoing shall not apply to any stock of brochures
or products existing at the time of such termination.

     9.3   Registered User Agreements. At LUMINEX's option and expense, LUMINEX
           --------------------------
and BIO-RAD shall enter into registered user agreements with respect to the
LUMINEX's Trademarks pursuant to applicable trademark law requirements
worldwide. BIO-RAD shall be responsible for proper filing of the registered user
agreement with government authorities worldwide. The parties shall share equally
all costs or fees associated with such filing.

                                  ARTICLE 10
                                CONFIDENTIALITY
                                ---------------

     10.1  Confidential Information. Each party may from time to time disclose
           ------------------------
to the other party, or such other party may otherwise learn, Confidential
Information. As used herein, "Confidential Information" shall mean any
information which if disclosed in tangible form is marked "Confidential" or with
other similar designation to indicate its confidential or proprietary nature or
if disclosed orally is indicated orally to be confidential or proprietary by the
disclosing party at the time of such disclosure. Notwithstanding the foregoing
or anything herein to the contrary, Confidential Information shall not include
any information that, in each case as demonstrated by written documentation: (i)
was already known to the receiving party, other than under an obligation of
confidentiality, at the time of disclosure; (ii) was generally available to the
public or otherwise part of the public domain at the time of its disclosure to
the receiving party; (iii) became generally available to the public or otherwise
part of the public domain after its disclosure and other than through any act or
omission of the receiving party in breach of this Agreement; (iv) was
subsequently lawfully disclosed to the receiving party by a person other than
the disclosing party; or (v) can be shown by the receiving party to have been
independently developed thereby.

     10.2  Confidentiality.  Each party agrees to hold and maintain in strict
           ---------------
confidence all Confidential Information.  Each party further agrees not to
disclose any Confidential Information except to those employees and consultants
who have a need to know and provided that each person to whom Confidential
Information is disclosed agrees to be bound by the same terms regarding the
disclosure and use of Confidential Information as set forth in this Article 10.
Without limiting the foregoing, neither party shall use Confidential Information
except as permitted by this Agreement, or as may be necessary to exercise its
rights or perform its obligations under this Agreement.  Nothing contained in
this Article 10 shall prevent either party from disclosing any Confidential
Information as is required by law or regulation to be disclosed; provided,
however, that the party disclosing Confidential Information under such a duty to
disclose has provided written notice to the other party promptly upon receiving
notice of such requirement in order to enable such other party to seek a
protective order or otherwise prevent disclosure of such Confidential
Information.

     10.3  Review of Publication. As soon as is practicable prior to the oral
           ---------------------
public disclosure, and prior to the submission to any outside person for public
dissemination of a manuscript describing the scientific data with respect to
Standard Beads or Magnetic Beads, in each case to the extent the contents of the
oral disclosure or manuscript have not been previously disclosed pursuant to
this Section 10.3 before such proposed disclosure, BIO-RAD shall disclose to
LUMINEX the disclosure or manuscript to be made or submitted, and shall allow
LUMINEX at least thirty (30) days to determine whether such disclosure or
manuscript contains subject matter for which patent protection should be sought
prior to publication or which LUMINEX reasonably believes should be modified to
avoid (i) disclosure of information of a confidential or proprietary nature, or
(ii) regulatory or other similar problems.

           (a)  Publication Rights. After the expiration of thirty (30) days
                ------------------
from the date of mailing such disclosure or manuscript, unless BIO-RAD has
received the written notice specified below, BIO-RAD shall be free to submit
such manuscript for publication or make the oral disclosure.

           (b)  Delay of Publication. Prior to the expiration of the thirty (30)
                --------------------
day period specified in Section 10.3(a) above, LUMINEX may notify BIO-RAD in
writing of its determination that such oral presentation or manuscript contains
confidential or objectionable material or material that consists of patentable

                                       16
<PAGE>

subject matter for which patent protection should be sought. If so notified,
BIO-RAD shall withhold its proposed public disclosure and the parties shall
mutually consult in good faith to determine the best course of action to take in
order to modify the disclosure or to obtain patent protection. After resolution
of the confidentiality, regulatory or other issues, including without limitation
the filing of a patent application, to both parties' reasonable satisfaction,
BIO-RAD shall be free to submit the manuscript and/or make its public oral
disclosure.

                                  ARTICLE 11
                     INTELLECTUAL PROPERTY INDEMNIFICATION
                     -------------------------------------

     11.1  LUMINEX Indemnity.  LUMINEX shall defend and/or settle any claim,
           -----------------
complaint, suit, proceeding or cause of action (collectively and individually
referred to as a "Claim") brought against BIO-RAD by a third party for
infringement of any third party copyright, trademark, trade secret or patent by
the Standard Beads or Luminex100 System, each as delivered by LUMINEX hereunder,
subject to the requirements of Section 11.2 below. LUMINEX shall pay all
resulting damages or settlement amounts finally awarded against BIO-RAD
(including reasonable attorneys' fees and court costs) together with any costs
of End Users or purchasers of the BIO-RAD System to the extent specifically
included under Section 11.4 below, in each event only to the extent attributable
to such Claim. Notwithstanding the provisions of this Section 11.1, LUMINEX will
not have any obligation under this Article 11 to the extent a Claim for
infringement is based upon (i) modified Standard Beads or Luminex100 System if
such infringement would have been avoided by use of the Standard Beads or
Luminex100 System as provided by LUMINEX (unless such modifications are made by
LUMINEX), (ii) use of the Standard Beads or Luminex100 System in applications or
for purposes other than for which the same were intended within the Fields, or
(iii) completed products or equipment or any assembly, combination, method or
process in which the Standard Beads or Luminex100 System are used, to the extent
the infringement would not have resulted if the Standard Beads and Luminex100
System were not incorporated into the BIO-RAD System. It is understood and
agreed that if the use of the Luminex100 System would infringe a third party
patent if used with Standard Beads bound to any analyte generally, the Claim of
infringement would be included as part of LUMINEX's indemnification obligations
under this Section 11.1.

     11.2  BIO-RAD Indemnity. At LUMINEX's written request, BIO-RAD shall defend
           -----------------
and/or settle any claim, complaint, suit, proceeding or cause of action
(collectively and individually referred to as a "Claim") brought against LUMINEX
by a third party for infringement of any third party copyright, trademark, trade
secret or patent by the (i) the BIO-RAD System except to the extent such Claim
is covered under Section 11.1 above, (ii) any Kit or assay sold by BIO-RAD for
use with the BIO-RAD System or Luminex100 System except to the extent such Claim
is covered under Section 11.1 above, or (iii) the manufacture or use of any of
the items set forth in (i) or (ii) above, subject to the requirements of Section
11.2 below. BIO-RAD shall pay all resulting damages or settlement amounts
finally awarded against LUMINEX (including reasonable attorneys' fees and court
costs) to the extent attributable to such Claim.

     11.3  Indemnification Procedure. The indemnified party shall (i) promptly
           -------------------------
notify the indemnifying party of each Claim, provided that the indemnifying
party shall only be excused from its indemnification obligations due to delay in
notice if and to the extent the indemnifying party is prejudiced by such delay,
(ii) provide the indemnifying party with sole control over the defense and/or
settlement thereof, and (iii) at the indemnifying party's request and expense,
provide full information and reasonable assistance to the indemnifying party
with respect to such Claims.

     11.4  Alternatives. Without limiting Section 11.1 above, if the Standard
           ------------
Beads or Luminex100 System are or in LUMINEX' reasonable judgment may become
subject of any Claim of infringement of third party intellectual property
rights, or if a court determines that the Standard Beads or Luminex100 System
infringe any third party intellectual property rights, LUMINEX, at its option
and expense, may (i) procure for BIO-RAD the right under such third party
intellectual property rights to use the Standard Beads or Luminex100 System in
accordance with the terms and conditions of this Agreement; or (ii) replace the
Standard Beads or Luminex100 System with other suitable noninfringing product
having functionality substantially the same as the Standard Beads or Luminex100
System so

                                       17
<PAGE>

replaced; or (iii) modify the Standard Beads or Luminex100 System to make the
same noninfringing provided they have substantially the same functionality as
the unmodified Standard Beads and Luminex100 System; or (iv) in the event (i),
(ii) or (iii) above are not commercially reasonable in LUMINEX's judgment,
terminate BIO-RAD's distribution rights with respect to the infringing subject
matter and at LUMINEX's option require that BIO-RAD remove the Standard Beads
and/or Luminex100 System or portion thereof from use. If LUMINEX requires
removal of Standard Beads and/or Luminex100 Systems, the costs of removal from
use of End Users or other purchasers of the BIO-RAD System shall be at LUMINEX's
expense, provided that BIO-RAD shall not incur any such costs without first
obtaining LUMINEX's prior written approval.

     11.5  Entire Liability. THE FOREGOING PROVISIONS OF THIS ARTICLE 11 STATE
           ----------------
THE ENTIRE LIABILITY AND OBLIGATIONS OF LUMINEX AND THE EXCLUSIVE REMEDY OF BIO-
RAD WITH RESPECT TO ANY ALLEGED INFRINGEMENT OF PATENT RIGHTS, TRADE SECRETS,
COPYRIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS WITH RESPECT TO THE STANDARD
BEADS, MAGNETIC BEADS OR LUMINEX100 SYSTEM.

                                  ARTICLE 12
                                 MISCELLANEOUS
                                 -------------

     12.1  Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND
           -------------
INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE UNITED STATES AND THE STATE OF
CALIFORNIA WITHOUT REFERENCE TO CONFLICT OF LAWS PRINCIPLES AND EXCLUDING THE
1980 U.N. CONVENTION ON CONTRACTS FOR THE INTERNATIONAL SALE OF GOODS.

     12.2  Disputes.  If LUMINEX and BIO-RAD, are unable to resolve any dispute
           --------
between them, either LUMINEX or BIO-RAD may, by written notice to the other,
have such dispute referred to the Chief Executive Officers (or equivalent) of
LUMINEX and BIO-RAD Vice-President Diagnostics Group, for attempted resolution
by good faith negotiations within fourteen (14) days after such notice is
received.  Unless otherwise mutually agreed, the negotiations between the
designated officers shall be conducted by telephone, within three (3) days and
at times within the period stated above offered by the designated officer of
BIO-RAD to the designated officer of LUMINEX for consideration.  If the parties
are unable to resolve such dispute in accordance with the aforementioned
procedure or within such fourteen (14) day period, either party shall have the
right to pursue any and all other remedies available to such party.

     12.3  Jurisdiction; Venue.  All disputes arising out of or related to this
           -------------------
Agreement, except disputes arising under Section 3.3(b) or Section 4.16 which
will be subject to arbitration pursuant to Section 12.5 below) will be subject
to the exclusive jurisdiction and venue of the California state courts of Contra
Costa County (or, if there is exclusive federal jurisdiction, the Northern
District Court of California), and the parties consent to the personal and
exclusive jurisdiction of these courts.

     12.4  Indemnity. Except for warranty claims for which LUMINEX is liable
           ---------
under Article 7 and infringement claims covered by Section 11.1, and claims to
the extent directly resulting from LUMINEX's negligence or willful misconduct,
BIO-RAD agrees to indemnify and hold LUMINEX, its officers, directors, employees
and agents harmless from and against any cost, loss, damages, liability or
expense (including attorneys' fees) arising out of third party claims brought
against LUMINEX, its officers, directors, employees or agents relating to use or
distribution by BIO-RAD of the Standard Beads, Magnetic Beads, BIO-RAD Systems
or Luminex100 Systems.

     12.5  Arbitration. Any dispute, controversy or claim arising out of Section
           -----------
3.3 or the establishment of royalties under Section 4.16(c) shall be settled by
binding arbitration in the manner described in this Section 12.5. The
arbitration shall be conducted pursuant to the Commercial Rules and
Supplementary Procedures for Large, Complex Disputes of the American Arbitration
Association then in effect.  Notwithstanding those rules, the following
provisions shall apply to the arbitration hereunder:

                                       18
<PAGE>

           (a)  Arbitrators. The arbitration shall be conducted by a single
                -----------
arbitrator; provided that at the request of either party, the arbitration shall
be conducted by a panel of three (3) arbitrators, with one (1) arbitrator chosen
by each of BIO-RAD and LUMINEX and the third appointed by the other two (2)
arbitrators. If the parties are unable to agree upon a single arbitrator, or the
third arbitrator in case of a panel of three (3), such single or third
arbitrator (as the case may be) shall be appointed in accordance with the rules
of the American Arbitration Association. In any event, the arbitrator or
arbitrators selected in accordance with this Section 12.5 are referred to herein
as the "Panel." With respect to disputes arising under Section 3.3(b) or the
establishment of royalties due under Section 4.16(c), the arbitrators shall be
independent experts in the in vitro diagnostics industry.
                           --------

           (b)  Proceedings. The parties and the arbitrators shall use their
                -----------
best efforts to complete the arbitration within sixty (60) days after the
appointment of the Panel under Section 12.5(a) above. The Panel shall, in
rendering its decision, apply the substantive law of the State of California,
without regard to its conflict of laws provisions, except that the
interpretation of and enforcement of this Section 12.5 shall be governed by the
U.S. Federal Arbitration Act. The proceeding shall take place in Contra Costa
County, California. The fees of the Panel shall be shared equally by the
parties. Neither party shall initiate an arbitration hereunder unless it has
attempted to resolve the matter in accordance with Section 12.1 above.

     12.6  Force Majeure. Except with respect to payment obligations,
           -------------
nonperformance of any party shall be excused to the extent that performance is
rendered impossible by strike, fire, earthquake, flood, governmental acts,
orders or restrictions, or other similar causes beyond the reasonable control of
the nonperforming party.

     12.7  Assignment. BIO-RAD's rights and obligations under this Agreement may
           ----------
not be assigned or otherwise transferred to a third party without the prior
written consent of LUMINEX which approval shall not be unreasonably withheld.
LUMINEX may assign or otherwise transfer its rights and obligations under this
Agreement without BIO-RAD's prior consent to a successor-in-interest to all or
substantially all of the business or assets of LUMINEX pertaining to the subject
matter hereof whether by merger, reorganization, asset sale or otherwise.  Any
attempted assignment by BIO-RAD in violation of this Section 12.7 shall be null
and void.  Subject to the foregoing, this Agreement shall be binding upon and
inure to the benefit of the parties hereto, their successors and assigns.
Notwithstanding the foregoing provisions of this Section 12.7 or any other
provision of this Agreement, in no event shall BIO-RAD gain any rights
whatsoever in an or to any product, technology, invention or other intellectual
property (i) that was conceived, developed or reduced to practice by any
successor-in-interest to the business or assets of LUMINEX pertaining to the
subject matter hereof prior to or after the effective date of the assignment or
other transfer of LUMINEX's business or assets pertaining to the subject matter
hereof ("Transfer").  It is further understood and agreed that the provisions of
Section 3.2 shall not apply to any Acquiror of LUMINEX with respect to products,
technologies, inventions or other intellectual property other than the
Luminex100 System and Beads as they exist at the effective date of the Transfer.

     12.8  Notices. Any notice or report required or permitted to be given or
           -------
made under this Agreement by either party shall be in writing and delivered to
the other party at its address indicated below (or to such other address as a
party may specify by notice hereunder) by courier or by registered or certified
airmail, postage prepaid, or by facsimile; provided, however, that all facsimile
notices shall be promptly confirmed, in writing, by registered or certified
airmail, postage prepaid.  All notices shall be effective as of the date
received by the addressee.

     If to LUMINEX:      Luminex Corporation
                         12212 Technology Boulevard
                         Austin, Texas 78727
                         Attention:  General Counsel
                         Fax:  (512) 258-4173

                                       19
<PAGE>

     If to BIO-RAD:           Bio-Rad Laboratories, Inc.
                              Corporate Offices
                              1000 Alfred Nobel Drive
                              Hercules, California 94547
                              Attention:  General Counsel
                              Fax: (510) 741-5815

                              with a copy to:
                              Bio-Rad Laboratories, Inc. Diagnostics Group
                              4000 Alfred Nobel Drive
                              Hercules, California 94547
                              Attention:  Vice-President, Diagnostics Group
                              Fax: (510) 741-6499

     12.9   Limitation of Liability. Except as otherwise expressly provided here
            -----------------------
in, neither party's liability arising out of this Agreement and/or the sale of
Standard Beads, Magnetic Beads and sale of Luminex100 Systems shall exceed to
the total amount paid by BIO-RAD to LUMINEX hereunder. IN NO EVENT SHALL EITHER
PARTY BE LIABLE TO THE OTHER PARTY OR ANY OTHER PERSON FOR ANY SPECIAL,
CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED
REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM OR RELATING TO THIS
AGREEMENT OR THE SUBJECT MATTER HEREOF, WHETHER BASED IN CONTRACT, TORT
(INCLUDING NEGLIGENCE) OR OTHERWISE, AND EVEN IF SUCH PARTY IS ADVISED OF THE
POSSIBILITY OR LIKELIHOOD OF SAME. THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING
ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN. THE
FOREGOING LIMITATIONS SHALL NOT APPLY TO LIABILITY OF BIO-RAD ARISING UNDER
LIABILITY OF LUMINEX ARISING UNDER ARTICLE 10 OR SECTION 3.2, 3.3 OR 11.1,
provided, however, that with respect to liability of LUMINEX arising under
--------- -------
Section 3.3, such liability shall not exceed the lower of (a) five million
($5,000,000) dollars, or (b) ten times the total amount paid by BIO-RAD to
LUMINEX hereunder.

     12.10  Confidential Terms. Except as expressly provided herein, each party
            ------------------
agrees not to disclose any terms of this Agreement to any third party without
the consent of the other party, except to prospective investors and to such
party's accountants, attorneys and other professional advisors or as required by
securities or other applicable laws, in which case the disclosing party shall
seek confidential treatment to the extent available.

     12.11  Foreign Corrupt Practices Act. In conformity with the United States
            -----------------------------
Foreign Corrupt Practices Act and BIO-RAD and its employees and agents shall not
directly or indirectly make any offer, payment, or promise to pay; authorize
payment; nor offer a gift, promise to give, or authorize the giving of anything
of value for the purpose of influencing any act or decision of an official of
any government (including a decision not to act) or inducing such a person to
use his or her influence to affect any such governmental act or decision in
order to assist LUMINEX in obtaining, retaining or directing any such business.

     12.12  Export Control. BIO-RAD further understands and acknowledges that
            --------------
LUMINEX is subject to regulation by agencies of the United States, including,
but not limited to, the U.S. Department of Commerce, which prohibit export or
diversion of certain products and technology to certain countries. Any and all
obligations of LUMINEX to provide the Standard Beads, Magnetic Beads or
Luminex100 System, as well as any other technical information or assistance
shall be subject in all respects to such laws and regulations as shall from time
to time govern the license and delivery of technology and products abroad by
persons subject to the jurisdiction of the United States, including without
limitation the U.S. Export Administration Act of 1979, as amended, any successor
legislation, and the Export Administration Regulations issued by the U.S.
Department of Commerce, Bureau of Export Administration. BIO-RAD agrees to
cooperate with LUMINEX including without limitation, providing required
documentation, in order to obtain export licenses or exemptions therefrom.
BIO-RAD agrees that it will

                                      20
<PAGE>

comply with the U.S. Export Administration Regulations and other laws and
regulations governing exports in effect from time to time. BIO-RAD further
agrees not to knowingly provide Standard Beads, Magnetic Beads, Luminex100
Systems or BIO-RAD Systems to any organization, public or private, which engages
in the research or production of military devices, armaments, or any instruments
of warfare, including biological, chemical and nuclear warfare.

     12.13  Headings. Headings included herein are for convenience only, do not
            --------
form a part of this Agreement and shall not be used in any way to construe or
interpret this Agreement.

     12.14  Non-Waiver. Any waiver of the terms and conditions hereof must be
            ----------
explicitly in writing. The waiver by either of the parties of any breach of any
provision hereof by the other shall not be construed to be a waiver of any
succeeding breach of such provision or a waiver of the provision itself.

     12.15  Severability. Should any section, or portion thereof, of this
            ------------
Agreement be held invalid by reason of any law, statute or regulation existing
now or in the future in any jurisdiction by any court of competent authority or
by a legally enforceable directive of any governmental body, either party may
terminate this Agreement by written notice to the other party within thirty (30)
days after such holding. If this Agreement is not so terminated, such section or
portion thereof shall be validly reformed so as to approximate the intent of the
parties as nearly as possible and, if unreformable, shall be deemed divisible
and deleted with respect to such jurisdiction, but the Agreement shall not
otherwise be affected.

     12.16  Independent Contractors. The relationship of BIO-RAD and LUMINEX
            -----------------------
established by this Agreement is that of independent contractors. Nothing in
this Agreement shall be construed to create any other relationship between BIO-
RAD and LUMINEX. Neither party shall have any right, power or authority to
assume, create or incur any expense, liability or obligation, express or
implied, on behalf of the other.

     12.17  Entire Agreement. The terms and provisions contained in the
            ----------------
Agreement, including the Exhibits hereto, constitute the entire agreement
between the parties and shall supersede all previous communications,
representations, agreements or understandings, either oral or written, between
the parties. The parties agree that the terms and conditions of this Agreement
shall prevail, notwithstanding contrary or additional terms, in any purchase
order, sales acknowledgment, confirmation or any other document issued by either
party effecting the sale of Standard Beads, Magnetic Beads or sale of Luminex100
Systems. No agreement or understanding varying or extending this Agreement shall
be binding upon either party hereto, unless set forth in a writing which
specifically refers to the Agreement signed by duly authorized officers or
representatives of the respective parties, and the provisions hereof not
specifically amended thereby shall remain in full force and effect.

     12.18  Counterparts. This Agreement may be executed in counterparts, each
             ------------
of which shall be deemed an original, but which together shall constitute one
and the same instrument.

     IN WITNESS WHEREOF, the parties hereto have caused their duly authorized
representatives to execute this Agreement.

BIO-RAD LABORATORIES, INC.                     LUMINEX CORPORATION

By: /s/ Sanford S. Wadler                      By: /s/ Mark Chandler
   -----------------------------                  -----------------------------

Name:  Sanford S. Wadler                       Name:  Mark Chandler
      --------------------------                    ---------------------------

Title: Vice President and General Counsel      Title: Chairman & CEO
      -----------------------------------            --------------------------

                                       21
<PAGE>

                                   EXHIBIT A
                                    FIELDS

1.  "Field One" means [**]
     ---------

2.  "Field Two" means [**]
     ---------

3.  "Field Three" means [**]
     -----------

4.  "Field Four" means [**]
     ----------

BIO-RAD may add, [**] an additional [**] analytes (either DNA or protein) to
each Field listed above which analytes are not included within the the Field
definitions at the Effective Date. The foregoing, right is exercisable by
written notice to LUMINEX of the analytes. In addition, BIO-RAD may expand each
Field listed above by an additional [**] analytes (either DNA or protein) by
written notice of such additional analytes and payment to LUMINEX of [**]
Dollars [**] per Field so expanded.

_________
[**] Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.

<PAGE>

                                   EXHIBIT B
                               END USER LICENSES

Label/Sticker for Luminex 100 System:

          No rights or licenses under any of Luminex's patents are granted by or
     shall be implied from the sale of this unit of Luminex100 instrumentation
     or license of Luminex software to you, the purchaser, and you do not
     receive any right under Luminex's patent rights by virtue of your purchase
     of Luminex100 instrumentation or license of Luminex software. You agree
     that the Luminex100 instrumentation and Luminex software are sold only for
     use with fluorescently labeled microsphere beads authorized by Luminex and
     you may obtain a royalty-free license under Luminex's patents, if any, to
     use this unit of Luminex100 instrumentation with fluorescently labeled
     microsphere beads authorized by Luminex by registering this unit of
     Luminex100 instrumentation with Luminex in accordance with the instructions
     accompanying the Luminex100 instrumentation.

     Label License/Sticker for Kit:

     By purchasing this Kit, which contains fluorescently labeled microsphere
beads authorized by Luminex, you, the customer, acquire the right under
Luminex's patent rights, if any, to use this Kit or any portion of this Kit,
including without limitation the microsphere beads contained herein, only with
Luminex's laser based fluorescent analytical test instrumentation marketed under
the name Luminex100.

           End-User License Agreement (EULA) for Luminex100(TM) Operating System

          This Luminex End-User License Agreement ("EULA") is a legal agreement
     between you (either an individual or a single entity) the end-user and
     Luminex Corporation ("Luminex") regarding the use of the Luminex software
     product identified above, which includes computer software and online or
     electronic documentation and may include associated media and printed
     materials (if any) ("SOFTWARE PRODUCT" or "SOFTWARE"). By clicking on the
     button below labeled "Accept", you represent that you have read, understand
     and agree to be bound by the terms of this EULA. If you do not agree to be
     bound by the terms of this EULA, please click on the button below labeled
     "Decline". If you do not agree to be bound by the terms of this EULA, you
     are not authorized to use the SOFTWARE PRODUCT and shall discontinue use
     immediately. Any unauthorized use is a violation of the law and acts as a
     total nullification of all warranties.

     The SOFTWARE PRODUCT is protected by copyright laws and international
copyright treaties, as well as other intellectual property laws and treaties.
The SOFTWARE PRODUCT is licensed, not sold.

1.  GRANT OF LICENSE. Subject to the terms and conditions of this EULA, Luminex
    hereby grants to you a nonexclusive, nontransferable, nonassignable license
    (without right to sublicense) under Luminex's copyrights and trade secrets
    to use the SOFTWARE PRODUCT on a hardware platform purchased from Luminex
    pursuant to Luminex's terms and conditions of sale. You may make one (1)
    copy of the SOFTWARE PRODUCT for backup or archival purposes only. Although
    no rights or licenses under any of Luminex's patents are granted by or shall
    be implied from the license of the SOFTWARE or the sale of Luminex100
    instrumentation to you, the purchaser, you may obtain a license under
    Luminex's patents, if any, to use this unit of Luminex100 instrumentation
    with fluorescently labeled microsphere beads authorized by Luminex by
    purchasing such beads from Luminex or an authorized Luminex reseller.

<PAGE>

2.  RESTRICTIONS.

 .   You must maintain all proprietary notices on all copies of the SOFTWARE
    PRODUCT.

 .   You may not distribute copies of the SOFTWARE PRODUCT to third parties.

 .   You may not reverse-engineer, decompile, disassemble, or otherwise attempt
    to derive source code from the SOFTWARE PRODUCT.

 .   You may not copy (other than one backup or archival copy), distribute,
    sublicense, rent, lease, transfer or grant any rights in or to all or any
    portion of the SOFTWARE PRODUCT.

 .   You must comply with all applicable laws regarding the use of the SOFTWARE
    PRODUCT.

 .   You may not modify or prepare derivative works of the SOFTWARE PRODUCT.

 .   You may not use the SOFTWARE PRODUCT in a computer-based service business or
    publicly display visual output of the SOFTWARE PRODUCT.

 .   You may not transmit the SOFTWARE PRODUCT over a network, by telephone, or
    electronically by any means.

3.  TERM AND TERMINATION. Your rights under this EULA are effective until
    termination. You may terminate this EULA at any time by destroying the
    SOFTWARE PRODUCT, including all computer programs and documentation, and
    erasing any copies residing on your computer equipment. Luminex may
    terminate this EULA upon thirty (30) days written notice to you. Your rights
    under this EULA automatically terminate without further action on the part
    of Luminex if you do not comply with any of the terms or conditions of this
    EULA. Upon any termination of this EULA, you agree to destroy the SOFTWARE
    PRODUCT and erase any copies residing on your computer equipment.

4.  RIGHTS IN SOFTWARE. All rights and title in and to the SOFTWARE PRODUCT and
    any copies thereof are owned by Luminex or its suppliers. This EULA is not a
    sale and does not transfer to you any title or ownership interest in or to
    the SOFTWARE or any patent, copyright, trade secret, trade name, trademark
    or other intellectual property right therein. You shall not remove, alter,
    or obscure any proprietary notices contained on or within the SOFTWARE and
    shall reproduce such notices on any back-up copy of the SOFTWARE. All title
    and intellectual property rights in and to the content which may be accessed
    through use of the SOFTWARE PRODUCT is the property of the respective
    content owner and may be protected by applicable copyright or other
    intellectual property laws and treaties. This EULA grants you no rights to
    use such content.

5.  EXPORT RESTRICTIONS. You agree that you will not export or re-export the
    SOFTWARE PRODUCT to any country, person, entity, or end-user subject to
    U.S.A. export restrictions. You hereby warrant no state or federal agency
    has suspended, revoked, or denied your export privileges.

6.  NO WARRANTY. THE SOFTWARE PRODUCT IS LICENSED "AS IS." ANY USE OF THE
    SOFTWARE PRODUCT IS AT YOUR OWN RISK. THE SOFTWARE PRODUCT IS PROVIDED FOR
    USE ONLY WITH LUMINEX PRODUCTS. TO THE MAXIMUM EXTENT PERMITTED BY
    APPLICABLE LAW, LUMINEX AND ITS SUPPLIERS DISCLAIM ALL WARRANTIES, EITHER
    EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF
    MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT.

                                       24
<PAGE>

7.  LIMITATION OF LIABILITY. IN NO EVENT SHALL LUMINEX OR ITS SUPPLIERS BE
    LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT, OR CONSEQUENTIAL DAMAGES
    WHATSOEVER (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF BUSINESS
    PROFITS, BUSINESS INTERRUPTION, LOSS OF BUSINESS INFORMATION, OR ANY OTHER
    PECUNIARY LOSS) ARISING OUT OF THE USE OF OR INABILITY TO USE THE SOFTWARE
    PRODUCT, EVEN IF LUMINEX HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
    DAMAGES.

8.  MISCELLANEOUS. This EULA is governed by the laws of the State of Texas,
    U.S.A., without reference to conflicts of laws principles. You shall not
    assign or sublicense or otherwise transfer the rights or license granted
    hereunder, by agreement or by operation of law, without the prior written
    consent of Luminex, and all assignments in violation of this prohibition
    shall be null and void. This EULA is the complete and exclusive agreement of
    Luminex and you and supersedes all other communications, oral or written,
    relating to the subject matter hereof. No change to this EULA shall be valid
    unless in writing and signed by the party against whom enforcement is
    sought. The waiver or failure of Luminex or you to exercise in any respect
    any right or rights provided for herein shall not be deemed a waiver of any
    further right hereunder. If any provision of this EULA is held
    unenforceable, the remainder of this EULA will continue in full force and
    effect.

                                       25
<PAGE>

                                   EXHIBIT C
                               LIMITED WARRANTY

     1.   Limited Warranty. LUMINEX warrants to BIO-RAD that for one year from
          ----------------
delivery to an End User, but no more than fifteen (15) months from delivery to
BIO-RAD, the Standard Beads and the Luminex100 System (for purposes of this
Exhibit C, each of the Standard Beads and Luminex100 System is referred to as a
"Product") substantially conform to LUMINEX's published functional
specifications therefor, subject to use in accordance with documentation
provided by LUMINEX that accompanies such Product, including but not limited to
the instructions-for-use; provided, that LUMINEX is reasonably satisfied that
the claimed nonconformities actually exist and were not caused by unusual
physical or electrical stress, misuse, neglect, alteration, improper
installation, unauthorized repair or improper testing. Notwithstanding the
foregoing, the warranty provided herein specifically excludes any software or
hardware not provided by LUMINEX. Subject to LUMINEX's warranty return policies
for Product set forth in paragraph 2 below, LUMINEX's sole liability and
BIO-RAD's exclusive remedy for breach of the foregoing warranty, shall be at
LUMINEX's option, repair or replacement of the Product with a conforming Product
or refund of a percentage of the fee paid by BIO-RAD for the Product which
percentage would be computed based on prior usage. Except as otherwise expressly
set forth in this Agreement, LUMINEX MAKES NO OTHER WARRANTIES OR CONDITION WITH
RESPECT TO THE PRODUCT, EXPRESS OR IMPLIED, AND SPECIFICALLY DISCLAIMS THE
IMPLIED WARRANTIES AND CONDITION OF MERCHANTABILITY, NONINFRINGEMENT AND FITNESS
FOR A PARTICULAR PURPOSE.

     Warranty Return Policies. In the event that a Product fails to conform to
     ------------------------
the warranty set forth in paragraph 1 above, during the warranty period (i)
BIO-RAD shall notify LUMINEX in a timely manner in writing that such Product
failed to conform and shall furnish a detailed explanation of any alleged
nonconformity; and (ii) at LUMINEX's option and election, BIO-RAD shall return
such nonconforming Product to LUMINEX F.O.B. (U.C.C.) LUMINEX's manufacturing
facility or destroy such Product and provide LUMINEX with written certification
of destruction. Except as expressly provided in this paragraph, BIO-RAD would
not have the right to return a Product to LUMINEX without LUMINEX's prior
written consent.

<PAGE>

                                   EXHIBIT D
                                  TRADEMARKS

     Luminex

     Luminex100

<PAGE>

                                   EXHIBIT E

                           LUMINEX100 SYSTEM PRICING
                           -------------------------

Product
Number                   Item Description
------                   ----------------

51-00001             Luminex100 System                     [**]
                                [**]

This Luminex100 Purchase Price will be effective during the first [**] years of
this Agreement, after which time LUMINEX may, at its option, increase the
Luminex100 Purchase Price effective on [**] days written notice to BIO-
RAD, provided that such increases may occur no more frequently than once per
year. Any increase in the Luminex100 Purchase Price shall be effective for all
Luminex100 Systems ordered after such notice.

_____________
[**] Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.<PAGE>

                                                                    EXHIBIT 10.8

     Confidential Materials omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote omissions.

                 AMENDMENT TO DEVELOPMENT AND SUPPLY AGREEMENT

     This Amendment to Development and Supply Agreement ("Amendment"), effective
as of January 13, 2000 (the "Amendment Effective Date"), by and between Luminex
Corporation, a Delaware corporation with principal offices at 12212 Technology
Boulevard, Austin, Texas 79727 ("LUMINEX") and Bio-Rad Laboratories, Inc., a
Delaware corporation with principal offices at 1000 Alfired Nobel Drive,
Hercules, California 94547 ("BIO-RAD") (LUMINEX and BIO-RAD collectively, the
"Parties"), amends that certain Development and Supply Agreement by and between
the Parties effective as of March 19, 1999 (the "Agreement").

     WHEREAS, the Parties desire to amend the Agreement as set forth herein
below.

     NOW, THEREFORE, the Parties agree as follows:

     AMENDMENT. This Amendment hereby amends the Agreement to incorporate the
terms and conditions set forth in this Amendment. The relationship of the
Parties shall continue to be governed by the terms and conditions of the
Agreement, as amended herein; and in the event that there is any conflict
between the terms and conditions of the Agreement and this Amendment, the term
and conditions of this Amendment shall control. As used in this Amendment, all
capitalized terms shall have the meanings defined for such terms in this
Amendment or, if not defined in the Amendment, the meanings defined in the
Agreement

MODIFICATIONS TO THE AGREEMENT.

I.  Exhibit A to the Agreement is hereby amended to add the following:

    [**]

2.       "Field Two" in Exhibit A of the Agreement is deleted and replaced with
         the following: [**]

3.       Section 1.7 of the Agreement is hereby amended to add the following:

         "Fields  Five and Six, as set forth in Exhibit A, shall be limited to
         Research Use.

4.       The Agreement is hereby amended to add the following Section 1.23:

-----------
[**] Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.
<PAGE>

         "1.23  "Research  Use" means the  performance  of basic life science
                 -------------
         research,  including high  throughput  screening,  but in all events
         excluding   laboratory   testing  for  human   clinical   diagnostic
         purposes."

  5.     Section 2.1 (d) of the Agreement is hereby amended to delete the last
         sentence of such section and replace it with the following:

         "Notwithstanding any provision of this Agreement to the contrary,
         including the provisions of Section 8.3, if the parties do not agree by
         June 1, 2000 upon: (i) a tolling fee for Magnetic Beads of less than or
         equal to [**] ($[**]) for every three thousand (3000) units of Magnetic
         Beads purchased, where a "unit" of Magnetic Beads is equal to one
         microsphere bead, and (ii) the development of a beadmap for Magnetic
         Beads which shall be capable of discriminating between [**] analytes
         with a minimum accuracy level of [**] percent ([**]%) and no more than
         [**] percent ([**]%) misclassification, all rights of BIO-RAD to have
         LUMINEX treat the Magnetic Beads hereunder and all obligations of
         LUMINEX with respect to the treatment or processing of Magnetic Beads
         for BIO-RAD hereunder shall automatically terminate unless otherwise
         agreed in writing, provided, however, that in such event BIO-RAD shall
                            --------  -------
         have the right to have the Magnetic Beads processed by BIO-RAD or a
         third party and, for the avoidance of doubt, BIO-RAD shall retain the
         exclusivity rights with respect to Magnetic Beads set forth in Section
         3.2 of this Agreement."

  6.     Section 3.1 of the Agreement is hereby amended to add the following
         after the phrase "only as part of BIO-RAD Systems":

         "'or, within Fields Five and Six, Luminex100 Systems separately"

  7.     Section 3.1 of the Agreement is hereby further amended to add the
         following after the phrase "BIO-RAD U.S. Diagnostics Division
         management":

         "or BIO-RAD U.S. Life Sciences Division management"

  8.     Section 3.1 of the Agreement is hereby further amended to add the
         following after the phrase "in conjunction with their operation of BIO-
         RAD Systems":

         "and Luminex100 Systems"

  9.     Section 3.3(b)(i) of the Agreement is hereby amended to add the
         following after the phrase "human clinical diagnostics industry":

         "or the life science research industry"

  10.    Section 3.5 of the Agreement is hereby amended to add the following
         after the phrase "BIO-RAD U.S. Diagnostics Division management":

         "or BIO-RAD U.S. Life Sciences Division management"

         ------------
         [**] Indicates that material has been omitted and confidential
         treatment requested therefor. All such material has been filed
         separately with the Commission pursuant to Rule 406.

                                      -2-
<PAGE>

  11.     Section 4.6(c) of the Agreement is hereby amended to add the following
          after the phrase "in vitro diagnostic Kits":
                            --------

          "or Kits for Research Use"

  12.     Section 4.8 of the Agreement is hereby amended to add the following
          after the phrase "All invoices shall be sent to the following
          address:"

          "For  Clinical  Diagnostics  Group,  Bio-Rad  Laboratories,   Accounts
          Payable, 4000 Alfred Nobel Drive,  Hercules,  California 49547, or for
          Life Sciences Group,  Bio Rad  Laboratories,  Accounts  Payable,  2000
          Alfred Nobel Drive, Hercules, California."

  13.     Section 4.11 (a) of the Agreement is hereby amended to add the
          following after the phrase "At the Effective Date:"

          "and at the Amendment Effective Date"

  14.     Section 4.11(b) of the Agreement is hereby amended to add the
          following after the phrase "the date of this Agreement:"

          "and at the Amendment Effective Date"

  15.     Section 5.2 of the Agreement is hereby amended to read in its entirety
          as follows:

          "Exclusivity of Efforts.  To avoid conflicts of interest,  BIO-RAD and
           ----------------------
          its Affiliates will not manufacture, market, sell or otherwise
          distribute any materials, technologies or products, other than
          Luminex100 Systems, Bio-Rad Systems and Kits, specifically designed
          for performing Multiplexed Bead Assays using flow cytometry based
          detection of particles for use in the human clinical diagnostics
          industry or for Research Use within the Fields. In addition, BIO-RAD
          agrees that except for performing its development obligations as
          agreed pursuant to Section 2.1 and the development and manufacture of
          Bio-Rad Systems, neither BIO-RAD's clinical diagnostics division or
          group nor BIO-RAD's life sciences division or group will directly or
          indirectly develop any materials, technologies or products
          specifically designed for performing Multiplexed Bead Assays within
          the Fields using flow cytometry based detection of particles. BIO-RAD
          further agrees that it will not provide research and development
          funding to or license any third party to develop, manufacture, market,
          sell or otherwise distribute any materials, technologies or products
          specifically designed for performing Multiplexed Bead Assays within
          the Fields using flow cytometry based detection of particles. It is
          understood that the foregoing sentence shall not apply to passive
          investments by BIO-RAD in equity of third parties for use in the human
          clinical diagnostics industry or for Research Use."

                                      -3-
<PAGE>

  16.     Section 8.1 of the Agreement is hereby amended to add the following
          after the words "each such renewal term":

          "but which in no case shall vary by more than [**] percent ([**]%)
          from the average of the three prior years' sales. Notwithstanding the
          foregoing provisions of this Section 8.1, Fields Five and Six shall be
          included in the Agreement during each of the renewal terms only if the
          parties agree upon and BIO-RAD meets annual sales goals with respect
          to Kits in Fields Five and Six, which annual sales goals shall be
          negotiated in good faith by the parties prior to the commencement of
          each such renewal term but which in no case shall vary by more than
          [**] percent ([**]%) from the average of the three prior years'
          sales."

  17.     Section 8.3 of the Agreement is hereby amended to add the following
          after the phrase "Luminex100 System" in the second line of that
          Section:

          "(or,  with  respect to Fields other than Fields One,  Two,  Three or
          Four, beginning five (5) years after the addition to the Agreement of
          such Field or Fields)"

  18.     Section 8.3 of the Agreement is hereby further amended to delete the
          last sentence thereof and replace if with the following:

          "If BIO-RAD has not made commercially available Kits incorporating
          Magnetic Beads in each of Fields One, Two, Three and Four within [**]
          years of the Effective Date plus any extension of time necessary to
          produce Magnetic Beads reasonably acceptable to BIO-RAD, LUMINEX may
          terminate BIO-RAD's exclusive rights with respect to Magnetic Beads in
          Fields One, Two, Three and Four by written notice to BIO-RAD. If BIO-
          RAD has not made commercially available Kits incorporating Magnetic
          Beads in each of Fields Five and Six within three (3) years of the
          Amendment Effective Date plus any extension of time necessary to
          produce Magnetic Beads reasonably acceptable to BIO-RAD, LUMINEX may
          terminate BIO-RAD's exclusive rights with respect to Magnetic Beads in
          Five and Six by written notice to BIO- RAD.

  19.     Section 12.2 of the Agreement is hereby amended to add the following
          after the word "Group" in the third line of that Section:

          "or BIO-RAD Vice-President Life Sciences Division, as appropriate,"

  20.     Section 12.8 of the Agreement is hereby amended to add the following
          at the end of that Section:

          "with a further copy to:
          Bio-Rad Laboratories, Inc. Life Science Group
          2000 Alfred Nobel Drive
          Hercules, California 94547
          Attention: Vice-President, Life Science Group"

--------------
[**]   Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.

                                      -4-

<PAGE>

      Fax: (510) 741-5803"

 21.  ADDITIONAL TERM: ADVANCE AGAINST ROYALTIES. Upon the effective date of
      this Amendment, BIO-RAD shall pay to LUMINEX an aggregate of [**] Dollars
      ($[**]) for both of Fields Five and Six as an Advance.

 22.  The additional fee for expansion of Field Two set forth in Exhibit A of
      the Agreement is waived.

 ENTIRE AGREEMENT.  Notwithstanding  the first sentence of Section 12.17 of the
    Agreement, together the Agreement (including the Exhibits thereto) and this
    Amendment constitute the entire agreement between the Parties in connection
    with the subject matter thereof and supersede all prior and contemporaneous
    agreements, understandings, negotiations and discussions, whether oral or
    written, of the Parties.

      IN WITNESS WHEREOF, the Parties have executed this Amendment.

  LUMINEX CORPORATION                                 BIO-RAD LABORATORIES, INC.

  By:    /s/ Randel S. Marfin                        By:    /s/ Sanford Wadler
        ----------------------                              --------------------
  Name:  Randel S. Marfin                            Name:  Sanford Wadler
        ----------------------                              --------------------
  Title: Vice President - Business Development       Title: Vice President
        --------------------------------------              --------------------

----------
[**] Indicates that material has been omitted and confidential treatment
requested therefor. All such material has been filed separately with the
Commission pursuant to Rule 406.

                                      -5-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}]]